<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">NnGmdc7NT7DtkVwPFpxmmdM</article-id>
      <article-id pub-id-type="other">00017</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2009001000017</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(09)09300417</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2009001000017</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Realce tardio e perfus&#227;o mioc&#225;rdica em cardiomiopatia hipertr&#243;fica (compara&#231;&#227;o entre grupos)</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Barbosa</surname>
            <given-names>Clarissa Almeida Sarmento</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Castro</surname>
            <given-names>Cl&#225;udio Campi de</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>&#193;vila</surname>
            <given-names>Luiz Francisco Rodrigues de</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Parga Filho</surname>
            <given-names>Jos&#233; Rodrigues</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hattem</surname>
            <given-names>Domingos Mohanad</given-names>
          </name>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fernandez</surname>
            <given-names>Edmundo Arteaga</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff02">
        <addr-line>
          <named-content content-type="city">Porto Alegre</named-content>
          <named-content content-type="state">RS</named-content>
        </addr-line>
        <institution content-type="orgname">Funda&#231;&#227;o Universit&#225;ria de Cardiologia do Rio Grande do Sul</institution>
      </aff>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade de S&#227;o Paulo</institution>
        <institution content-type="orgdiv1">Faculdade de Medicina </institution>
        <institution content-type="orgdiv2">Instituto do Cora&#231;&#227;o</institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>10</month>
        <year>2009</year>
      </pub-date>
      <volume>93</volume>
      <issue>4</issue>
      <fpage>426</fpage>
      <lpage>433</lpage>
      <history>
        <date date-type="accepted">
          <day>04</day>
          <month>03</month>
          <year>2008</year>
        </date>
        <date date-type="rev-recd">
          <day>13</day>
          <month>02</month>
          <year>2008</year>
        </date>
        <date date-type="received">
          <day>02</day>
          <month>10</month>
          <year>2007</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: A resson&#226;ncia magn&#233;tica &#233; um m&#233;todo eficaz para estudo da cardiomiopatia hipertr&#243;fica. OBJETIVO: Avaliar, pela resson&#226;ncia magn&#233;tica, os par&#226;metros de fun&#231;&#227;o sist&#243;lica, perfus&#227;o e viabilidade mioc&#225;rdica em pacientes portadores de cardiomiopatia hipertr&#243;fica, comparando os grupos com e sem obstru&#231;&#227;o na via de sa&#237;da do ventr&#237;culo esquerdo. M&#201;TODO: Vinte e um pacientes com diagn&#243;stico de cardiomiopatia hipertr&#243;fica realizaram estudos de fun&#231;&#227;o, viabilidade e perfus&#227;o mioc&#225;rdica nas fases de estresse e de repouso pela resson&#226;ncia magn&#233;tica. RESULTADOS: Os segmentos ventriculares mais comprometidos pela hipertrofia foram os da regi&#227;o septal. O grupo obstrutivo apresentou distribui&#231;&#227;o segmentar de espessura mioc&#225;rdica semelhante ao n&#227;o-obstrutivo, por&#233;m com maiores m&#233;dias que o primeiro grupo. A m&#233;dia da fra&#231;&#227;o de eje&#231;&#227;o dos pacientes do grupo obstrutivo foi maior que o grupo n&#227;o-obstrutivo, enquanto as m&#233;dias dos volumes sist&#243;lico e diast&#243;lico finais foram menores no grupo obstrutivo. Houve correla&#231;&#227;o positiva entre a espessura segmentar do ventr&#237;culo e a massa segmentar do realce tardio. A indu&#231;&#227;o de estresse determinou aumento do n&#250;mero de segmentos com altera&#231;&#227;o de perfus&#227;o e essa altera&#231;&#227;o foi mais evidente no grupo obstrutivo. CONCLUS&#195;O: Os segmentos ventriculares com maior espessura s&#227;o os septais. As regi&#245;es hipertr&#243;ficas est&#227;o associadas &#224; maior extens&#227;o de realce tardio. Houve correla&#231;&#227;o positiva entre as &#225;reas de hipertrofia ventricular e perfus&#227;o mioc&#225;rdica alterada, e esses achados foram mais evidentes no grupo obstrutivo.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Perfus&#227;o mioc&#225;rdica</kwd>
        <kwd>cardiomiopatia hipertr&#243;fica</kwd>
        <kwd>estudo comparativo</kwd>
        <kwd>imagem de resson&#226;ncia magn&#233;tica</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>24</day>
        <month>11</month>
        <year>2009</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>ARTIGO ORIGINAL </p>
    <p> TOMOGRAFIA/RESSON&#194;NCIA</p>
    <p>
      <bold>Realce tardio e perfus&#227;o mioc&#225;rdica em cardiomiopatia hipertr&#243;fica (compara&#231;&#227;o entre grupos)</bold>
    </p>
    <p>
      <bold>Clarissa Almeida Sarmento Barbosa<sup>I</sup>; Cl&#225;udio Campi de Castro<sup>I</sup>; Luiz Francisco Rodrigues de &#193;vila<sup>I</sup>; Jos&#233; Rodrigues Parga Filho<sup>I</sup>; Domingos Mohanad Hattem<sup>II</sup>; Edmundo Arteaga Fernandez<sup>I</sup></bold>
    </p>
    <p><sup>I</sup>Faculdade de Medicina da Universidade de S&#227;o Paulo (USP) - Instituto do Cora&#231;&#227;o (Incor), S&#227;o Paulo, SP </p>
    <p><sup>II</sup>Funda&#231;&#227;o Universit&#225;ria de Cardiologia do Rio Grande do Sul (FUCRS), Porto Alegre, RS</p>
    <p>
      <xref ref-type="corresp" rid="back">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO:</bold> A resson&#226;ncia magn&#233;tica &#233; um m&#233;todo eficaz para estudo da cardiomiopatia hipertr&#243;fica. </p>
    <p><bold>OBJETIVO: </bold> Avaliar, pela resson&#226;ncia magn&#233;tica, os par&#226;metros de fun&#231;&#227;o sist&#243;lica, perfus&#227;o e viabilidade mioc&#225;rdica em pacientes portadores de cardiomiopatia hipertr&#243;fica, comparando os grupos com e sem obstru&#231;&#227;o na via de sa&#237;da do ventr&#237;culo esquerdo. </p>
    <p><bold>M&#201;TODO:</bold> Vinte e um pacientes com diagn&#243;stico de cardiomiopatia hipertr&#243;fica realizaram estudos de fun&#231;&#227;o, viabilidade e perfus&#227;o mioc&#225;rdica nas fases de estresse e de repouso pela resson&#226;ncia magn&#233;tica. </p>
    <p><bold>RESULTADOS:</bold> Os segmentos ventriculares mais comprometidos pela hipertrofia foram os da regi&#227;o septal. O grupo obstrutivo apresentou distribui&#231;&#227;o segmentar de espessura mioc&#225;rdica semelhante ao n&#227;o-obstrutivo, por&#233;m com maiores m&#233;dias que o primeiro grupo. A m&#233;dia da fra&#231;&#227;o de eje&#231;&#227;o dos pacientes do grupo obstrutivo foi maior que o grupo n&#227;o-obstrutivo, enquanto as m&#233;dias dos volumes sist&#243;lico e diast&#243;lico finais foram menores no grupo obstrutivo. Houve correla&#231;&#227;o positiva entre a espessura segmentar do ventr&#237;culo e a massa segmentar do realce tardio. A indu&#231;&#227;o de estresse determinou aumento do n&#250;mero de segmentos com altera&#231;&#227;o de perfus&#227;o e essa altera&#231;&#227;o foi mais evidente no grupo obstrutivo. </p>
    <p><bold>CONCLUS&#195;O:</bold> Os segmentos ventriculares com maior espessura s&#227;o os septais. As regi&#245;es hipertr&#243;ficas est&#227;o associadas &#224; maior extens&#227;o de realce tardio. Houve correla&#231;&#227;o positiva entre as &#225;reas de hipertrofia ventricular e perfus&#227;o mioc&#225;rdica alterada, e esses achados foram mais evidentes no grupo obstrutivo.</p>
    <p><bold>Palavras-chave:</bold> Perfus&#227;o mioc&#225;rdica; cardiomiopatia hipertr&#243;fica; estudo comparativo; imagem de resson&#226;ncia magn&#233;tica.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>As cardiomiopatias s&#227;o doen&#231;as de causas desconhecidas que se caracterizam por um envolvimento prim&#225;rio do mioc&#225;rdio ventricular, n&#227;o sendo, portanto, secund&#225;rias &#224;s enfermidades preexistentes do cora&#231;&#227;o ou da circula&#231;&#227;o<sup>1</sup>.</p>
    <p>A cardiomiopatia hipertr&#243;fica (CMH) &#233; caracterizada pela hipertrofia do mioc&#225;rdio sem causa aparente<sup>2</sup>.</p>
    <p>A doen&#231;a resulta de anormalidades gen&#233;ticas comprovadas em aproximadamente 63% dos pacientes<sup>3,4</sup>. Os principais genes relacionados &#224; doen&#231;a est&#227;o localizados no cromossomo 14 - o <italic>locus</italic> respons&#225;vel pela cadeia pesada da &#946;-miosina card&#237;aca; no cromossomo 1 - o <italic>locus</italic> respons&#225;vel pela troponina T; e no cromossomo 11, respons&#225;vel pela liga&#231;&#227;o da miosina &#224; prote&#237;na C<sup>5</sup>.</p>
    <p>Habitualmente, a doen&#231;a se manifesta clinicamente na adolesc&#234;ncia, com hipertrofia mioc&#225;rdica progressiva durante o per&#237;odo de crescimento r&#225;pido, mas ocasionalmente pode se apresentar na inf&#226;ncia ou at&#233; mesmo antes do nascimento<sup>6</sup>.</p>
    <p>Os pacientes com CMH podem ser classificados em obstrutivos e n&#227;o-obstrutivos, quanto &#224; obstru&#231;&#227;o ao fluxo sangu&#237;neo na via de sa&#237;da do ventr&#237;culo esquerdo (VE). A obstru&#231;&#227;o exibe importante papel no progn&#243;stico e na evolu&#231;&#227;o cl&#237;nica<sup>7</sup>, sendo, portanto, um fator independente importante no desenvolvimento de sintomas graves de insufici&#234;ncia card&#237;aca e de morte<sup>2</sup>. O estudo Doppler-ecocardiogr&#225;fico caracteriza como significativo o tipo de CMH obstrutiva com gradientes intraventriculares de mais que 30 mmHg<sup>8</sup>.</p>
    <p>Investiga&#231;&#245;es epidemiol&#243;gicas demonstraram preval&#234;ncias estimadas da express&#227;o fenot&#237;pica da CMH, na popula&#231;&#227;o adulta em geral, de aproximadamente 0,2% (1:500). Presume-se que existam cerca de 320.000 portadores da mol&#233;stia em nosso pa&#237;s<sup>9</sup>. Foi realizado estudo em centro de refer&#234;ncia do nosso meio que demonstrou maior incid&#234;ncia da CMH em adultos jovens, com discreto predom&#237;nio no sexo feminino. As formas obstrutivas foram observadas em 53% dos pacientes<sup>9</sup>.</p>
    <p>A hipertrofia do ventr&#237;culo esquerdo (VE) &#233; caracteristicamente assim&#233;trica, sendo a parede mais comumente comprometida a septal anterior, mas ocasionalmente pode ser encontrada a forma conc&#234;ntrica do VE que envolve igualmente o septo e a parede livre do ventr&#237;culo<sup>2</sup>.</p>
    <p>Durante muito tempo, o ecocardiograma bidimensional foi considerado o m&#233;todo de imagem "padr&#227;o-ouro" para avalia&#231;&#227;o da CMH<sup>10</sup>.</p>
    <p>Estudos comparativos entre o ecocardiograma e a resson&#226;ncia magn&#233;tica (RM) card&#237;aca demonstraram maior capacidade deste &#250;ltimo m&#233;todo diagn&#243;stico em estudar de forma completa todos os segmentos do VE, principalmente nos casos em que a afec&#231;&#227;o interessa a outros segmentos do cora&#231;&#227;o, que n&#227;o o septo interventricular, como ocorre nas formas apicais de hipertrofia<sup>2</sup>.</p>
    <p>A RM permite avaliar, de forma semelhante ao ecocardiograma, os par&#226;metros de fun&#231;&#227;o ventricular contr&#225;til, por&#233;m apresenta maior acur&#225;cia no c&#225;lculo de volumes, massa e fra&#231;&#227;o de eje&#231;&#227;o (FE), j&#225; que utiliza modelos geom&#233;tricos combinando a morfologia do VE com figuras matem&#225;ticas. A RM se tornou, portanto, a t&#233;cnica de refer&#234;ncia nos casos em que o c&#225;lculo exato da fra&#231;&#227;o de eje&#231;&#227;o &#233; necess&#225;rio<sup>10</sup>. A RM permite ainda a avalia&#231;&#227;o dos par&#226;metros de viabilidade mioc&#225;rdica e de altera&#231;&#245;es perfusionais<sup>11</sup>.</p>
    <p>Este estudo teve como objetivo avaliar a perfus&#227;o e a viabilidade mioc&#225;rdica em pacientes com CMH por meio do m&#233;todo de RM.</p>
    <p>
      <bold>M&#233;todos</bold>
    </p>
    <p>Foram estudados 21 pacientes, de forma prospectiva, durante o per&#237;odo de dezembro de 2002 a agosto de 2005, provenientes da Unidade Cl&#237;nica de Miocardiopatias do Instituto do Cora&#231;&#227;o (InCor) da Faculdade de Medicina da Universidade de S&#227;o Paulo (HCFMUSP), com diagn&#243;stico confirmado de CMH. O diagn&#243;stico de CMH foi baseado na demonstra&#231;&#227;o ecocardiogr&#225;fica de hipertrofia assim&#233;trica do VE, na aus&#234;ncia de qualquer enfermidade card&#237;aca ou sist&#234;mica capaz de ocasion&#225;-la. O crit&#233;rio considerado para o diagn&#243;stico de hipertrofia foi espessura telediast&#243;lica do septo do VE <underline>&gt;</underline> 15 mm<sup>12</sup>.</p>
    <p>Esse protocolo de estudo foi iniciado ap&#243;s a aprova&#231;&#227;o da Comiss&#227;o de &#201;tica do HC e do InCor. Cada paciente teve uma explana&#231;&#227;o oral e escrita sobre as propostas e os objetivos do trabalho e assinou um Termo de Consentimento p&#243;s-informado.</p>
    <p>Foram incluidos pacientes com idade de 18 a 60 anos, diagn&#243;stico pr&#233;vio de CMH assim&#233;trica e fun&#231;&#227;o de VE normal, confirmada pelo ecocardiograma. Exclu&#237;ram-se os pacientes com contra-indica&#231;&#227;o absoluta para realiza&#231;&#227;o de RM - aqueles com cardiomiopatia hipertensiva, ritmo n&#227;o-sinusal, transplante card&#237;aco pr&#233;vio, estenose a&#243;rtica confirmada, defeitos card&#237;acos cong&#234;nitos, infarto do mioc&#225;rdio pr&#233;vio e arritmias complexas. Os pacientes foram divididos em dois grupos: hipertr&#243;ficos obstrutivos e n&#227;o-obstrutivos. O crit&#233;rio utilizado para considerar obstru&#231;&#227;o significativa foi a presen&#231;a de gradientes intraventriculares de mais que 30 mmHg<sup>8</sup>.</p>
    <p>Foi obtida via de acesso venoso (gelco 18) conectada &#224; bomba injetora para a administra&#231;&#227;o de contraste em veia antecubital, modelo Spectris MR Injector - Medrad, Pittsburgh, PA, USA. O t&#243;rax foi rotineiramente preparado para a monitora&#231;&#227;o com quatro eletrodos (Hewlett Packard MR, Massachusetts, USA) na regi&#227;o precordial.</p>
    <p>O contraste utilizado foi o gadopentetato de dimeglumina, associado ao &#225;cido dietilenetriamino penta-ac&#233;tico (Gd-DTPA) (Magnevist<sup>&#174;</sup> - Schering AG, Berlin, Alemanha). A dose utilizada nesse protocolo foi de 0,1 mMol/kg em cada etapa de perfus&#227;o (estresse e repouso), dose considerada segura em pacientes com boa condi&#231;&#227;o cl&#237;nica.</p>
    <p>Foram obtidas sequ&#234;ncias localizadoras em tr&#234;s planos (<italic>Single Shot</italic> EPI), com acoplamento de ECG prospectivo com tempo de repeti&#231;&#227;o de 9 ms (TR = 9 ms), tempo de eco de 4 ms (TE = 4 ms), <italic>Flip angle</italic> (FA) = 40 &#186;, espessura de corte de 10 mm, n&#250;mero de excita&#231;&#245;es (NEX) de 2 a 4, campo de vis&#227;o (FOV) de 380 a 420 mm, e matriz de 128 x 128, interpoladas para 256 linhas.</p>
    <p>A partir do localizador sagital, obteve-se o eixo longo do VE utilizando a sequ&#234;ncia de gradiente eco (<italic>Single Shot</italic> EPI), com acoplamento de ECG prospectivo com tempo de repeti&#231;&#227;o de 9 ms (TR = 9 ms), tempo de eco de 4,0 ms (TE = 4 ms), <italic>Flip angle</italic> (FA) = 40 &#186;, espessura de corte de 10 mm, n&#250;mero de excita&#231;&#245;es (NEX) de 2 a 4, campo de vis&#227;o (FOV) de 380 a 420 mm, e matriz de 128 x 128, interpoladas para 256 linhas (corte em 4 c&#226;maras) para obten&#231;&#227;o da cine RM.</p>
    <p>A partir do corte 4 c&#226;maras, fez-se o planejamento do eixo curto do VE para a an&#225;lise da perfus&#227;o mioc&#225;rdica. A sequ&#234;ncia de pulso de perfus&#227;o utilizada foi <italic>Enhanced Fast Gradient Echo Train</italic> (EFGRET).</p>
    <p>Ap&#243;s a aquisi&#231;&#227;o em eixo curto do VE (6 a 8 cortes), o est&#237;mulo farmacol&#243;gico para hiperemia foi realizado com dipiridamol na dose de 0,54 mg/kg do peso corporal, infundido em 4 minutos. No pico de a&#231;&#227;o do dipiridamol (aproximadamente no segundo minuto ap&#243;s o t&#233;rmino da infus&#227;o), foi administrado gadol&#237;nio (Magnevist - Schering) em <italic>bolus</italic> na dose de 0,1 mMol/kg de peso (0,2 ml/kg de peso).</p>
    <p>Ao final da aquisi&#231;&#227;o das imagens de perfus&#227;o, administramos aminofilina na dose de 3 mg/kg de peso corporal (m&#225;ximo de 5 mg/kg) para antagonizar os efeitos vasodilatadores do dipiridamol. Considerava-se que o paciente havia retornado &#224;s condi&#231;&#245;es iniciais do exame quando a frequ&#234;ncia card&#237;aca (FC) voltava aos patamares observados no in&#237;cio do estudo. Quando a FC voltou ao normal, iniciamos a aquisi&#231;&#227;o em repouso. Nos estudos de perfus&#227;o de primeira passagem, a aquisi&#231;&#227;o da sequ&#234;ncia de estresse antes do repouso deve ser realizada pela necessidade de obter uma primeira passagem de contraste em um m&#250;sculo sem contraste. Repetimos a sequ&#234;ncia de perfus&#227;o com nova inje&#231;&#227;o de gadol&#237;nio na dose de 0,1 mMol/kg, (0,2 ml/kg de peso) para obten&#231;&#227;o de padr&#227;o basal da perfus&#227;o repouso.</p>
    <p>Foram feitas imagens do eixo curto e eixo longo do VE usando a sequ&#234;ncia Fast Card VT, acoplado ao ECG, FOV: 32-36, matriz: 256 x 192, espessura: 8,0 mm, <italic>Flip angle</italic>: 20 &#218;, <italic>Prep Pulse</italic> (TI): vari&#225;vel, com m&#233;dia de150 ms, NEX: 2, para a identifica&#231;&#227;o do realce tardio (RT).</p>
    <p>As imagens obtidas foram submetidas a p&#243;s-processamento com o <italic>software</italic> Report Card 3.0, de propriedade comercial da General Eletric Medical System (Milwaukee, WI, EUA) para avalia&#231;&#227;o da espessura segmentar do VE no eixo curto dos 17 segmentos, de acordo com os par&#226;metros definidos pela American Heart Association em 2002 (<xref ref-type="fig" rid="f01">Fig.1</xref>).</p>
    <p content-type="asset">
      <fig id="f01">
        <graphic xlink:href="1678-4170-abc-93-04-0426-00017-gf01.jpg"/></fig>
    </p>
    <p>Para avaliar a massa do VE, foram tra&#231;adas manualmente as bordas epic&#225;rdicas e endoc&#225;rdicas, excluindo os m&#250;sculos papilares e as trabecula&#231;&#245;es nas imagens da fase diast&#243;lica final. O volume final do VE foi calculado pelo m&#233;todo de Simpson, multiplicando cada &#225;rea mioc&#225;rdica planimetrada pela espessura de corte (10,0 mm) e somando os volumes das sec&#231;&#245;es obtidas separadamente. A massa mioc&#225;rdica foi calculada multiplicando o volume pela densidade do mioc&#225;rdio (1,05 g/ml). Os c&#225;lculos do VSF e do VDF foram realizados de maneira similar, utilizando as &#225;reas de eixo curto diast&#243;lico final e sist&#243;lico final, respectivamente. O volume ejetivo foi calculado subtraindo o VSF do VDF. Calculou-se a fra&#231;&#227;o FE global dividindo o volume-contra&#231;&#227;o pelo VDF.</p>
    <p>As imagens de mioc&#225;rdio com realce tardio (RT) (mioc&#225;rdio branco) foram planimetradas no eixo curto ap&#243;s identifica&#231;&#227;o visual destas, considerando significativa a diferen&#231;a de intensidade de sinal &gt; 2 desvios padr&#245;es acima do restante do mioc&#225;rdio. Essas &#225;reas foram mensuradas em cada um dos 17 segmentos de acordo com a segmenta&#231;&#227;o utilizada pela American Heart Association e classificadas quanto &#224; distribui&#231;&#227;o em difusa e confluente.</p>
    <p>Os dados de perfus&#227;o foram avaliados, com o m&#233;todo de identifica&#231;&#227;o visual associado &#224; diferen&#231;a da intensidade de sinal entre as &#225;reas de mioc&#225;rdio normal e as de perfus&#227;o alterada nas fases de repouso e estresse, por dois observadores experientes em cada um dos 17 segmentos. As &#225;reas de d&#233;ficit de perfus&#227;o ficam pretas, enquanto o restante do mioc&#225;rdio fica branco com a capta&#231;&#227;o do contraste. Ap&#243;s a avalia&#231;&#227;o de cada observador, realizou-se a correla&#231;&#227;o dos dados. N&#227;o foram consideradas como &#225;reas de d&#233;ficit de perfus&#227;o aquelas que apresentavam RT. Os resultados divergentes entre os observadores foram unificados de maneira consensual.</p>
    <p>
      <bold>An&#225;lise estat&#237;stica</bold>
    </p>
    <p>Para compara&#231;&#227;o das vari&#225;veis an&#225;lise das vari&#225;veis cont&#237;nuas, utilizaram-se m&#233;dia, desvio padr&#227;o (dp), mediana e valores m&#237;nimo e m&#225;ximo. Para as vari&#225;veis categ&#243;ricas, utilizaram-se frequ&#234;ncias absoluta e relativa. O padr&#227;o de espessura segmentar do VE foi analisado pelas t&#233;cnicas ANOVA (an&#225;lise de vari&#226;ncia) e de compara&#231;&#245;es m&#250;ltiplas pelo m&#233;todo de Tukey. As compara&#231;&#245;es da FE, VDF e VSF foram obtidas por meio do teste t para amostras independentes. O grau de correla&#231;&#227;o entre a espessura do VE e a massa do RT foi obtido pelo m&#233;todo de Pearson, para cada um dos segmentos. Os dados da avalia&#231;&#227;o da perfus&#227;o em repouso e em estresse foram apresentados de forma descritiva. Considerou-se signific&#226;ncia estat&#237;stica para n&#237;veis de p &lt; 0,05. As an&#225;lises foram feitas com o <italic>software</italic> estat&#237;stico Minitab, vers&#227;o 14.0.</p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>Dos 21 pacientes com CMH, 10 fizeram parte do grupo n&#227;o-obstrutivo e 11 do grupo obstrutivo, considerando o gradiente-limite na via de sa&#237;da de 30 mmHg para o grupo obstrutivo em estudo ecocardiogr&#225;fico. A propor&#231;&#227;o de pacientes do sexo masculino foi maior no grupo n&#227;o-obstrutivo, por&#233;m n&#227;o-significante, de acordo com o teste exato de Fisher (p/ =/ 0,659). N&#227;o houve diferen&#231;a estat&#237;stica entre a idade m&#233;dia dos pacientes entre os grupos, de acordo com o teste t para amostras independentes, sendo 32,3 anos no grupo n&#227;o-obstrutivo e 36,5 anos no obstrutivo. (<xref ref-type="fig" rid="g1">Gr&#225;ficos 1</xref> e <xref ref-type="fig" rid="g2">2</xref>).</p>
    <fig id="g1">
      <graphic xlink:href="1678-4170-abc-93-04-0426-00017-gf02.jpg"/></fig>
    <fig id="g2">
      <graphic xlink:href="1678-4170-abc-93-04-0426-00017-gf03.jpg"/></fig>
    <p>A distribui&#231;&#227;o do RT foi classificada em difusa e confluente. O tipo difuso foi subdividido em transeptal e septal ventricular direito e o confluente, em multifocal, subendoc&#225;rdico e da jun&#231;&#227;o ventricular<sup>12</sup>. No presente estudo, predominou a forma de distribui&#231;&#227;o difusa transeptal (n = 10), seguida da forma confluente multifocal (n = 6).</p>
    <p>As maiores m&#233;dias de espessura do VE foram dos segmentos basal &#226;ntero-septal, basal &#237;nfero-septal, m&#233;dio-&#226;ntero-septal e m&#233;dio-&#237;nfero-septal (2, 3, 8 e 9), e a menor m&#233;dia encontrada do segmento apical. Pelo teste ANOVA, foi poss&#237;vel verificar que, de fato, existe diferen&#231;a estat&#237;stica significante entre essas m&#233;dias (p &lt; 0,001). As compara&#231;&#245;es m&#250;ltiplas realizadas pelo teste de Tukey confirmaram os achados (<xref ref-type="fig" rid="f02">Fig. 2</xref>).</p>
    <p content-type="asset">
      <fig id="f02">
        <graphic xlink:href="1678-4170-abc-93-04-0426-00017-gf04.jpg"/></fig>
    </p>
    <p>A m&#233;dia da FE no grupo de pacientes com CMH obstrutiva foi maior do que no grupo n&#227;o-obstrutivo (m&#233;dia &#177; desvio padr&#227;o = 77,6&#177;7,8% no grupo obstrutivo e 71,0&#177;12,2% no grupo n&#227;o-obstrutivo), por&#233;m n&#227;o houve diferen&#231;a significativa, de acordo com o resultado do teste t para amostras independentes (p = 0,156) (<xref ref-type="fig" rid="g3">Gr&#225;ficos 3</xref> e <xref ref-type="fig" rid="g4">4</xref>).</p>
    <fig id="g3">
      <graphic xlink:href="1678-4170-abc-93-04-0426-00017-gf05.jpg"/></fig>
    <fig id="g4">
      <graphic xlink:href="1678-4170-abc-93-04-0426-00017-gf06.jpg"/></fig>
    <p>Tanto a m&#233;dia do VSF quanto a do VDF foram menores no grupo obstrutivo quando comparadas com o grupo n&#227;o-obstrutivo, por&#233;m n&#227;o houve diferen&#231;a significativa de acordo com o teste t para amostras independentes (VSF p = 0,495 e VDF p = 0,643).</p>
    <p>A correla&#231;&#227;o entre a espessura segmentar do VE e a massa segmentar do RT foi estatisticamente significante na maior parte das avalia&#231;&#245;es, isto &#233;, nos segmentos basal-anterior, &#226;ntero-septal, &#237;nfero-septal, basal-inferior, m&#233;dio-anterior, m&#233;dio-&#226;ntero-septal, m&#233;dio-&#237;nfero-lateral, apical-anterior, apical-septal e apical-lateral (1, 2, 3, 4, 7, 8, 11, 13, 14 e 16). Em todos esses segmentos, a correla&#231;&#227;o foi positiva, ou seja, quanto maior a espessura segmentar, maior a massa segmentar do RT.</p>
    <p>A massa total do VE foi semelhante nos grupos obstrutivo e n&#227;o-obstrutivo, n&#227;o havendo diferen&#231;a estat&#237;stica significante entre eles (p = 0,901). A massa total do RT tamb&#233;m n&#227;o apresentou diferen&#231;a estat&#237;stica significante entre os grupos (p/ =/ 0,194), por&#233;m a m&#233;dia foi menor no grupo obstrutivo (19,7/ g) do que no grupo n&#227;o-obstrutivo (48,8 g). A correla&#231;&#227;o linear entre esses dois par&#226;metros - massa do VE e massa do RT - foi positiva e significante, r = 0,613 (p = 0,003). Analisando os grupos separadamente, tamb&#233;m houve correla&#231;&#227;o positiva e significante, com r = 0,725 (p = 0,012) para o grupo obstrutivo e r = 0,756 (p = 0,011) para o grupo n&#227;o-obstrutivo.</p>
    <p>O n&#250;mero de segmentos com perfus&#227;o alterada foi maior nos pacientes obstrutivos (63,9%) quando comparados com os n&#227;o-obstrutivos (30%). Os segmentos mais comprometidos nos pacientes n&#227;o-obstrutivos foram os 3 e 4 (basal-&#237;nfero-septal e basal-inferior), enquanto no grupo obstrutivo foram os 2, 3 e 8 (basal &#226;ntero-septal, basal &#237;nfero-septal e m&#233;dio &#226;ntero-septal).</p>
    <p>A maior parte dos pacientes do grupo avaliado n&#227;o apresentou d&#233;ficit de perfus&#227;o na fase de repouso, somente 1 paciente do grupo obstrutivo e 1 do n&#227;o-obstrutivo. Ap&#243;s a indu&#231;&#227;o do estresse, mais 7 pacientes (5 obstrutivos e 2 n&#227;o-obstrutivos) passaram a apresentar altera&#231;&#227;o de perfus&#227;o em algum segmento. A compara&#231;&#227;o estat&#237;stica, pelo teste de qui-quadrado, mostrou ainda que, na perfus&#227;o de estresse, mais segmentos s&#227;o comprometidos (p &lt; 0,001), quando comparados &#224; de repouso.</p>
    <p>Houve correla&#231;&#227;o positiva entre a maior espessura do VE com &#225;reas focais de d&#233;ficit de perfus&#227;o, sendo no grupo n&#227;o-obstrutivo, nos segmentos 1 (basal-anterior), 2 (basal-&#226;ntero-septal), 3 (basal-&#237;nfero-septal), 7 (m&#233;dio-anterior) e 8 (m&#233;dio &#226;ntero-septal); enquanto no obstrutivo essa correla&#231;&#227;o se mostrou evidente somente nos segmentos 2 (basal &#226;ntero-septal), 3 (basal &#237;nfero-septal),14 (apical-septal) e 15 (apical-inferior). Considerando os dois grupos em conjunto, a correla&#231;&#227;o foi mais evidente nos segmentos 1 (basal-anterior), 3 (basal &#237;nfero-septal), 7 (m&#233;dio-anterior) e 14 (apical-septal).</p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>A op&#231;&#227;o por estudar os aspectos morfol&#243;gicos e fisiol&#243;gicos dos dois grupos de pacientes portadores de CMH (obstrutivos e n&#227;o-obstrutivos) pela RM baseou-se na premissa de que as diferen&#231;as entre os gradientes interventriculares e entre a espessura dos segmentos ventriculares comprometidos pela hipertrofia poderiam revelar importantes achados de imagem, &#250;teis para o manejo diagn&#243;stico, terap&#234;utico e progn&#243;stico desses pacientes.</p>
    <p>Conforme esperado, considerando a sele&#231;&#227;o pr&#233;via no presente estudo de pacientes com hipertrofia septal assim&#233;trica pelo ecocardiograma, a avalia&#231;&#227;o da espessura segmentar nos grupos obstrutivo e n&#227;o-obstrutivo evidenciou predom&#237;nio de maior espessura do VE nos segmentos 2 (basal-&#226;ntero-septal), 3 (basal-&#237;nfero-septal), 8 (m&#233;dio-&#226;ntero-septal) e 9 (m&#233;dio-&#237;nfero-septal) - (p &lt; 0,001) -, e menor espessura no segmento 17 (apical) nos dois grupos. Um estudo pr&#233;vio realizou avalia&#231;&#227;o do papel da RM na determina&#231;&#227;o da magnitude da hipertrofia do VE em pacientes com CMH, comparando os achados da RM com dados ecocardiogr&#225;ficos e constatou, de maneira semelhante ao nosso estudo, que a hipertrofia predominou na regi&#227;o do septo ventricular anterior tanto no ecocardiograma quanto na RM<sup>13</sup>. Apesar de a por&#231;&#227;o anterior do septo ventricular ser a &#225;rea mais comumente envolvida no processo de hipertrofia, o espessamento parietal focal pode comprometer outras &#225;reas do mioc&#225;rdio, como septo posterior, &#225;pice, parede &#226;ntero-lateral ou at&#233; mesmo a parede livre posterior<sup>2,14,15</sup>. Em rela&#231;&#227;o aos grupos obstrutivo e n&#227;o-obstrutivo, a sobreposi&#231;&#227;o das curvas das m&#233;dias das espessuras ventriculares segmentares mostrou distribui&#231;&#227;o linear de aspecto semelhante nos dois grupos, sendo obtidas m&#233;dias discretamente maiores no grupo dos pacientes obstrutivos somente em alguns segmentos, por&#233;m sem signific&#226;ncia estat&#237;stica. Esse dado sugere que a obstru&#231;&#227;o n&#227;o &#233; o fator determinante para o aumento da espessura/ mioc&#225;rdica.</p>
    <p>N&#227;o houve diferen&#231;a estat&#237;stica significante entre as m&#233;dias da FE nos grupos de hipertr&#243;ficos obstrutivos e n&#227;o-obstrutivos Esses dados revelam que a obstru&#231;&#227;o na via de sa&#237;da do VE n&#227;o interferiu diretamente na FE, pelo menos no nosso grupo em estudo. Vale ressaltar que, neste trabalho, os par&#226;metros de fun&#231;&#227;o sist&#243;lica foram avaliados na fase de repouso. Esse dado tem relev&#226;ncia considerando que alguns pacientes t&#234;m obstru&#231;&#227;o l&#225;bil, ou seja, ausente no repouso, mas provocada com altera&#231;&#245;es na pr&#233;-carga, p&#243;s-carga e contratilidade.</p>
    <p>Estudo em pacientes portadores da CMH, causada pela substitui&#231;&#227;o do &#225;cido asp&#225;rtico com asparagina (muta&#231;&#227;o Asp 175Asn) no gene, para investigar a rela&#231;&#227;o entre o d&#233;ficit contr&#225;til do mioc&#225;rdio e a hipertrofia do VE pela RM demonstrou, de maneira semelhante a este estudo, que n&#227;o h&#225; diferen&#231;a na medida da FE dos pacientes hipertr&#243;ficos (58%) em rela&#231;&#227;o ao grupo-controle (61%), por&#233;m os estudiosos observaram que os valores de encurtamento fracional foram menores nos pacientes hipertr&#243;ficos do que nos controles (62%)<sup>11</sup>.</p>
    <p>No presente estudo, os valores de VSD e VDF foram menores no grupo obstrutivo quando comparados ao n&#227;o-obstrutivo, apesar de os dados n&#227;o serem estatisticamente significantes (VSF p = 0,495 e VDF p = 0,643). Dados da literatura demonstraram que a CMH obstrutiva est&#225; associada ao desempenho contr&#225;til hiperdin&#226;mico do VE, apresentando n&#237;vel de FE pouco acima do normal, com complac&#234;ncia e disfun&#231;&#227;o diast&#243;lica com limites abaixo do normal, o que provavelmente decorre dos v&#225;rios graus de hipertrofia compensat&#243;ria associada &#224; express&#227;o fenot&#237;pica vari&#225;vel<sup>15</sup>.</p>
    <p>No presente estudo, houve correla&#231;&#227;o positiva entre o aumento da espessura ventricular segmentar com a presen&#231;a de altera&#231;&#227;o de perfus&#227;o segmentar somente em alguns segmentos. Vale ressaltar que houve dificuldade em obter dados com signific&#226;ncia estat&#237;stica, considerando que o n&#250;mero de pacientes com segmentos comprometidos foi pequeno nos dois grupos.</p>
    <p>Avaliando a perfus&#227;o de primeira passagem nas fases de repouso e de estresse em 17 pacientes, Sipola e cols.<sup>16</sup> demonstraram que o grau do d&#233;ficit de perfus&#227;o em pacientes com CMH estava associado &#224; intensidade da hipertrofia ventricular, o que sugere que tais defeitos estavam relacionados possivelmente ao fen&#243;tipo desses pacientes. Ainda neste estudo, observou-se que houve correla&#231;&#227;o negativa entre a espessura ventricular m&#225;xima e o &#237;ndice de reserva global e segmentar da primeira passagem do contraste (intensidade de sinal <italic>vs</italic> curva de tempo)<sup>16</sup>. Esses achados sugerem que a isquemia ocorre mais nos locais hipertr&#243;ficos e &#233; um fator de risco potencial &#224; morte s&#250;bita entre pacientes com CMH, especialmente os jovens. Dessa forma, a extens&#227;o da hipertrofia parece estar relacionada ao aumento do risco de morte s&#250;bita.</p>
    <p>No presente estudo, a maior parte dos pacientes n&#227;o apresentou d&#233;ficit de perfus&#227;o na fase de repouso, por&#233;m, na perfus&#227;o de estresse, mais segmentos s&#227;o comprometidos, principalmente no grupo obstrutivo. Esses achados t&#234;m implica&#231;&#227;o cl&#237;nica importante, sugerindo que a isquemia &#233; fator de risco na patog&#234;nese da morte s&#250;bita entre pacientes com CMH, especialmente os jovens. Esses dados podem tamb&#233;m ter valor progn&#243;stico, pois demonstram que, al&#233;m das margens das &#225;reas de realce tardio (mioc&#225;rdio substitu&#237;do por fibrose/col&#225;geno), existem focos de altera&#231;&#227;o perfusional (isqu&#234;mico), principalmente durante o estresse.</p>
    <p>A correla&#231;&#227;o positiva entre as regi&#245;es com maior espessura segmentar do VE e a massa segmentar do RT foi verificada na maior parte dos segmentos avaliados no presente estudo. Evidenciou-se, de maneira semelhante, correla&#231;&#227;o positiva e significante, r = 0,613 (p = 0,003), entre a massa total do VE e a massa total do RT, inclusive entre os grupos, com r = 0,725 (p = 0,012) para o grupo obstrutivo e r = 0,756 (p = 0,011) para o grupo n&#227;o-obstrutivo. Esses achados podem estar relacionados &#224; presen&#231;a de desarranjo fascicular mioc&#225;rdico associado a numerosas "fendas" teciduais e destrui&#231;&#227;o da arquitetura circular normal na camada muscular m&#233;dia nas regi&#245;es de mioc&#225;rdio hipertrofiado<sup>17</sup>, permitindo o dep&#243;sito aumentado do contraste associado &#224; depura&#231;&#227;o mais lenta deste, conforme discutido anteriormente. Nos locais em que existem fibrose e aumento do espa&#231;o extracelular, h&#225; maior ac&#250;mulo do gadol&#237;nio-DTPA, e a cin&#233;tica de distribui&#231;&#227;o deste &#233; mais lenta do que no mioc&#225;rdio normal. Esses dois efeitos resultam em uma concentra&#231;&#227;o do gadol&#237;nio retardada e persistente, em &#225;reas do cora&#231;&#227;o em que o espa&#231;o extracelular &#233; anormal<sup>18,19</sup>.</p>
    <p>Moon e cols.<sup>20</sup> realizaram estudo histopatol&#243;gico no cora&#231;&#227;o de um paciente de 28 anos com CMH que foi submetido a transplante card&#237;aco com obten&#231;&#227;o de imagens de RM do tecido hipertr&#243;fico. Os pesquisadores encontraram excesso de col&#225;geno entremeado &#224;s c&#233;lulas mioc&#225;rdicas que compunham at&#233; 20% do material examinado. Eles tamb&#233;m afirmaram que havia distribui&#231;&#227;o preferencial para o mesoc&#225;rdio, mais que o endoc&#225;rdio ou no epic&#225;rdio. Ainda segundo esse relato, havia distribui&#231;&#227;o semelhante das fibras mioc&#225;rdicas que se mostravam desarranjadas, mas esse achado era independente da presen&#231;a ou n&#227;o do col&#225;geno. O aspecto mais relevante, por&#233;m, &#233; o de que as &#225;reas com maior presen&#231;a de RT correspondiam &#224;quelas nas quais existia maior presen&#231;a de col&#225;geno, refor&#231;ando a hip&#243;tese de que a maior intensidade de contraste na fase tardia, ap&#243;s a inje&#231;&#227;o do meio do contraste paramagn&#233;tico, corresponde &#224;s regi&#245;es nas quais h&#225; maior presen&#231;a de col&#225;geno<sup>20</sup>.</p>
    <p>Da mesma forma que no presente estudo, v&#225;rios autores confirmaram a presen&#231;a de RT em pacientes com CMH, evidenciando a correla&#231;&#227;o positiva entre aumento da espessura da parede ventricular e extens&#227;o do RT<sup>21,22</sup>.</p>
    <p>
      <bold>Conclus&#227;o</bold>
    </p>
    <p>Este estudo comprovou que a RM foi capaz de avaliar de forma eficaz os par&#226;metros globais de fun&#231;&#227;o sist&#243;lica, perfus&#227;o e viabilidade mioc&#225;rdica na CMH.</p>
    <p>Ficou evidenciado que os segmentos ventriculares mais comprometidos pela hipertrofia s&#227;o os septais e que essa distribui&#231;&#227;o &#233; semelhante nos grupos obstrutivo e n&#227;o-obstrutivo, por&#233;m com espessuras m&#233;dias maiores no primeiro grupo.</p>
    <p>As regi&#245;es com maior espessura segmentar do VE apresentaram tamb&#233;m maior massa segmentar do RT.</p>
    <p>A despeito do fato de n&#227;o haver signific&#226;ncia estat&#237;stica, houve maior n&#250;mero de segmentos com altera&#231;&#227;o de perfus&#227;o no grupo com CMH obstrutiva, principalmente ap&#243;s a indu&#231;&#227;o do estresse.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>Este artigo &#233; parte de tese de Doutorado de Clarissa Almeida Sarmento pelo Instituto do Cora&#231;&#227;o (INCOR) da Universidade de S&#227;o Paulo (USP).</p>
    <p>
      <fn id="back" fn-type="corresp">
        <p>Correspond&#234;ncia:</p>
        <p> Clarissa Almeida Sarmento Barbosa </p>
        <p> Alameda Tenente Fernando Tuy, 139 </p>
        <p> Ed. Jardim de Floren&#231;a - Itaigara </p>
        <p> 40000-000 - Salvador, BA, Brasil </p>
        <p> E-mail: </p>
        <p>
          <email xlink:href="clarasarmentobarbosa@hotmail.com">clarasarmentobarbosa@hotmail.com</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 02/10/07; revisado recebido em 13/02/08; aceito em 04/03/08.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <mixed-citation>1. Braunwald's heart disease review and assessment /by/ Leonardo Lilly. 7<sup>th</sup> ed. Boston: Elsevier; 2005.</mixed-citation>
        <element-citation publication-type="book">
          <source>Braunwald's heart disease review and assessment /by/ Leonardo Lilly</source>
          <date>
            <year>2005</year>
          </date>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Maron BJ. Hypertrophic    cardiomyopathy: a systematic review. JAMA. 2002; 287 (10): 1308-20.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Hypertrophic cardiomyopathy: a systematic review</article-title>
          <source>JAMA</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>1308</fpage>
          <lpage>20</lpage>
          <issue>10</issue>
          <volume>287</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Maron</surname>
              <given-names>BJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Watkins H, Rosenweig    A, Hwang DS, Levi T, McKenna W, Seidman JG. Characteristics and prognostic implications    of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl    J Med. 1992; 326: 1108-14.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>1108</fpage>
          <lpage>14</lpage>
          <volume>326</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Watkins</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Rosenweig</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hwang</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Levi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>McKenna</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Seidman</surname>
              <given-names>JG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Watkins H. Multiple    disease gene cause hypertrophic cardiomyopathy. Br Heart J. 1994; 72 (Suppl.):S4-S9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Multiple disease gene cause hypertrophic cardiomyopathy</article-title>
          <source>Br Heart J</source>
          <date>
            <year>1994</year>
          </date>
          <fpage>S4</fpage>
          <lpage>S9</lpage>
          <volume>72</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Watkins</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Tirone AP, Arteaga    E, Pereira AC, Krieger JE, Buck PC, Ianni BM, et al. Research of markers for    the genes of heavy chain of cardiac &#946;-myosin    and myosin binding protein C in relatives of patients with hypertrophic cardiomyopathy.    Arq Bras Cardiol. 2005; 84: 467-72.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Research of markers for the genes of heavy chain of cardiac &#223;-myosin and myosin binding protein C in relatives of patients with hypertrophic cardiomyopathy</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>467</fpage>
          <lpage>72</lpage>
          <volume>84</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Tirone</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Arteaga</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Pereira</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Krieger</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Buck</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Ianni</surname>
              <given-names>BM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Mohiddin S,    Fananapazir L. Advances in understanding hypertrophic cardiomyopathy. Hospital    Practice. 2001: 15: 23-36.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Advances in understanding hypertrophic cardiomyopathy</article-title>
          <source>Hospital Practice</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>23</fpage>
          <lpage>36</lpage>
          <volume>15</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mohiddin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Fananapazir</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Elliott PM,    Blanes JRG, Mahon NG, Poloniecki JD, Mckenna WJ. Relation between severity of    left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy.    Lancet. 2001; 357: 420-4.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy</article-title>
          <source>Lancet</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>420</fpage>
          <lpage>4</lpage>
          <volume>357</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Elliott</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Blanes</surname>
              <given-names>JRG</given-names>
            </name>
            <name>
              <surname>Mahon</surname>
              <given-names>NG</given-names>
            </name>
            <name>
              <surname>Poloniecki</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Mckenna</surname>
              <given-names>WJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Nishimura RA,    Holmes Jr DR. Hypertrophic obstructive cardiomyopathy. N Engl J Med. 2004; 350    (13): 1320-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Hypertrophic obstructive cardiomyopathy</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>1320</fpage>
          <lpage>7</lpage>
          <issue>13</issue>
          <volume>350</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Nishimura</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Holmes Jr</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Artega E, Ianni    BM, Fernandes F, Mady C. Benign outcome in a long-term follow-up of patients    with hypertrophic cardiomyopathy in Brazil. Am Heart J. 2005; 159: 1099-105.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Benign outcome in a long-term follow-up of patients with hypertrophic cardiomyopathy in Brazil</article-title>
          <source>Am Heart J</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>1099</fpage>
          <lpage>105</lpage>
          <volume>159</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Artega</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ianni</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Fernandes</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Mady</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Di Cesare E.    MRI of the cardiomyopathies. Eur J Radiol. 2001; 38: 179-84.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>MRI of the cardiomyopathies</article-title>
          <source>Eur J Radiol</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>179</fpage>
          <lpage>84</lpage>
          <volume>38</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Di Cesare</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Sipola P, Lauerma    K, J&#228;&#228;skel&#228;inen P, Laakso M, Peuhkurinen K, Manninen H, et al.    Cine MR imaging of myocardial contractile impairment in patients with hypertrophic    cardiomyopathy attributable to Asd175Asn mutation in the &#945;-Tropomyosin    gene. Radiology. 2005; 236: 815-24.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cine MR imaging of myocardial contractile impairment in patients with hypertrophic cardiomyopathy attributable to Asd175Asn mutation in the &#945;-Tropomyosin gene</article-title>
          <source>Radiology</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>815</fpage>
          <lpage>24</lpage>
          <volume>236</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sipola</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lauerma</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>J&#228;&#228;skel&#228;inen</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Laakso</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Peuhkurinen</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Manninen</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Moon JCC, McKenna    WJ, McCrohon JA, Elliot PM, Smith GC, Pennell DJ. Toward clinical risk assessment    in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance.    J Am Coll Cardiol. 2003; 41 (9): 1561-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>1561</fpage>
          <lpage>7</lpage>
          <issue>9</issue>
          <volume>41</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Moon</surname>
              <given-names>JCC</given-names>
            </name>
            <name>
              <surname>McKenna</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>McCrohon</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Elliot</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>GC</given-names>
            </name>
            <name>
              <surname>Pennell</surname>
              <given-names>DJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Rickers C,    Wilke NM, Jerosch-Herold M, Casey AS, Panse P, Panse N, et al. Utility of cardiac    magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy.    Circulation. 2005; 112: 855-61.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy</article-title>
          <source>Circulation</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>855</fpage>
          <lpage>61</lpage>
          <volume>112</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rickers</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Wilke</surname>
              <given-names>NM</given-names>
            </name>
            <name>
              <surname>Jerosch-Herold</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Casey</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Panse</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Panse</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Klues HG, Schffers    A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy    I hypertrophic cardiomyopathy: morphologic observations and significance as    assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol.    1995; 26: 1699-708.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Phenotypic spectrum and patterns of left ventricular hypertrophy I hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>1699</fpage>
          <lpage>708</lpage>
          <volume>26</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Klues</surname>
              <given-names>HG</given-names>
            </name>
            <name>
              <surname>Schffers</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Maron</surname>
              <given-names>BJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Borer JS. Left    ventricular hypertrophy in hypertrophic cardiomyopathy. What's in a phenotype?    J Am Coll Cardiol. 2004; 44: 406-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Left ventricular hypertrophy in hypertrophic cardiomyopathy. What's in a phenotype?</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>406</fpage>
          <lpage>8</lpage>
          <volume>44</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Borer</surname>
              <given-names>JS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Sipola P, Lauerma    K, Husso-Saastamoinen M, Kuikka JT, Vanninen E, Laitinen T, et al. First-pass    MR imaging in the assessment of perfusion impairment in patients with hypertrophic    cardiomyopathy and the Asp175Asn mutation of the &#945;-Tropomyosin    gene. Radiology. 2003; 226: 129-37.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>First-pass MR imaging in the assessment of perfusion impairment in patients with hypertrophic cardiomyopathy and the Asp175Asn mutation of the &#945;-Tropomyosin gene</article-title>
          <source>Radiology</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>129</fpage>
          <lpage>37</lpage>
          <volume>226</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sipola</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lauerma</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Husso-Saastamoinen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kuikka</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Vanninen</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Laitinen</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Kuribayashi    T, Roberts WC. Myocardial disarray at junction of ventricular septum and left    and right free walls in hypertrophic cardiomyopathy. Am J Cardiol. 1992; 70:    1333-40.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Myocardial disarray at junction of ventricular septum and left and right free walls in hypertrophic cardiomyopathy</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>1333</fpage>
          <lpage>40</lpage>
          <volume>70</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kuribayashi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>WC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Kim RJ, Judd    RM. Gadolinium-Enhanced magnetic resonance imaging in hypertrophic cardiomyopathy.    J Am Coll Cardiol. 2003; 41: 1568-72.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Gadolinium-Enhanced magnetic resonance imaging in hypertrophic cardiomyopathy</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>1568</fpage>
          <lpage>72</lpage>
          <volume>41</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Judd</surname>
              <given-names>RM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Kim RJ, Wu    E, Rafael A, Chen EL, Parker MA, Simonetti O, et al. The use of contrast-enhanced    magnetic resonance imaging identify reversible myocardial dysfunction N Engl    J Med. 2000; 343: 1445-53.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The use of contrast-enhanced magnetic resonance imaging identify reversible myocardial dysfunction N Engl</article-title>
          <source>J Med</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>1445</fpage>
          <lpage>53</lpage>
          <volume>343</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Rafael</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Parker</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Simonetti</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Moon JCC, Reed    E, Sheppard MN, Elkington AG, Ho SY, Burke M, et al. The histologic basis of    late gadolinium enhancement cardiovascular magnetic resonance in hypertophic    cardiomyopathy. J Am Coll Cardiol. 2004; 43: 2260-4.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertophic cardiomyopathy</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>2260</fpage>
          <lpage>4</lpage>
          <volume>43</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Moon</surname>
              <given-names>JCC</given-names>
            </name>
            <name>
              <surname>Reed</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Sheppard</surname>
              <given-names>MN</given-names>
            </name>
            <name>
              <surname>Elkington</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Burke</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Choudhury L,    Mahrholdt H, Wagner A, Choi KM, Elliott M, Klocke FJ, et al. Myocardial scarring    in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy.    J Am Coll Cardiol. 2002; 40: 2156-64.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>2156</fpage>
          <lpage>64</lpage>
          <volume>40</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Choudhury</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Mahrholdt</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wagner</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Elliott</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Klocke</surname>
              <given-names>FJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. Moon JC, Mogensen    J, Elliott PM, Smith GC, Elkington AG, Prasad SK, et al. Myocardial late gadolinium    enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy    caused by mutations in troponin I. Heart. 2005; 91: 1036-40.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutations in troponin I</article-title>
          <source>Heart</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>1036</fpage>
          <lpage>40</lpage>
          <volume>91</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Moon</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Mogensen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Elliott</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>GC</given-names>
            </name>
            <name>
              <surname>Elkington</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Prasad</surname>
              <given-names>SK</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Late enhancement and myocardial perfusion in hypertrophic cardiomyopathy (comparison betw een groups)</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: The magnetic resonance imaging (MRI) is an effective method to study hypertrophic cardiomyopathy (HCM). OBJECTIVE: To evaluate, using MRI, the parameters of systolic function, perfusion and myocardial viability in patients with HCM, comparing the groups with and without obstruction of the left ventricular outflow tract. METHODS: Twenty-one patients with a diagnosis of HCM underwent the assessment of myocardial function, viability and perfusion under stress and at rest through MRI. RESULTS: The ventricular segments most severely impaired by hypertrophy were those of the septal region. The obstructive group presented segmental myocardial thickening distribution similar to the non-obstructive group, but with higher means than the first group. The mean ejection fraction of the patients in the obstructive group was higher than in the non-obstructive group, whereas the means of the end systolic and diastolic volumes were lower in the obstructive group. There was a positive correlation between the ventricular segmental thickening and the late enhancement segmental mass. The stress induction resulted in an increase in the number of segments with perfusion alterations and this alteration was more evident in the obstructive group. CONCLUSION: The thickest ventricular segments are the septal ones. The hypertrophic regions are associated to a greater extension of late enhancement. There was a positive correlation between the areas of ventricular hypertrophy and altered myocardial perfusion and these findings were more evident in the obstructive group.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Myocardial perfusion</kwd>
        <kwd>hypertrophic cardiomyopathy</kwd>
        <kwd>comparative study</kwd>
        <kwd>resonance imaging</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ORIGINAL ARTICLE</bold>
      </p>
      <p>
        <fn id="top-body2">
          <label>
            <bold>Late enhancement and myocardial perfusion in hypertrophic cardiomyopathy (comparison between groups)</bold>
          </label>
          <p>
            <bold>Clarissa Almeida Sarmento Barbosa<sup>I</sup>; Cl&#225;udio Campi de Castro<sup>I</sup>; Luiz Francisco Rodrigues de &#193;vila<sup>I</sup>; Jos&#233; Rodrigues Parga Filho<sup>I</sup>; Domingos Mohanad Hattem<sup>II</sup>; Edmundo Arteaga Fernandez<sup>I</sup></bold>
          </p>
        </fn>
      </p>
      <p><sup>I</sup>Faculdade de Medicina da Universidade de S&#227;o Paulo (USP) - Instituto do Cora&#231;&#227;o (Incor), S&#227;o Paulo, SP</p>
      <p><sup>II</sup>Funda&#231;&#227;o Universit&#225;ria de Cardiologia do Rio Grande do Sul (FUCRS), Porto Alegre, RS</p>
      <p>Mailing Address</p>
      <p>
        <bold>SUMMARY</bold>
      </p>
      <p><bold>BACKGROUND: </bold> The magnetic resonance imaging (MRI) is an effective method to study hypertrophic cardiomyopathy (HCM).</p>
      <p><bold>OBJECTIVE:</bold> To evaluate, using MRI, the parameters of systolic function, perfusion and myocardial viability in patients with HCM, comparing the groups with and without obstruction of the left ventricular outflow tract.</p>
      <p><bold>METHODS:</bold> Twenty-one patients with a diagnosis of HCM underwent the assessment of myocardial function, viability and perfusion under stress and at rest through MRI.</p>
      <p><bold>RESULTS:</bold> The ventricular segments most severely impaired by hypertrophy were those of the septal region. The obstructive group presented segmental myocardial thickening distribution similar to the non-obstructive group, but with higher means than the first group. The mean ejection fraction of the patients in the obstructive group was higher than in the non-obstructive group, whereas the means of the end systolic and diastolic volumes were lower in the obstructive group. There was a positive correlation between the ventricular segmental thickening and the late enhancement segmental mass. The stress induction resulted in an increase in the number of segments with perfusion alterations and this alteration was more evident in the obstructive group.</p>
      <p><bold>CONCLUSION:</bold> The thickest ventricular segments are the septal ones. The hypertrophic regions are associated to a greater extension of late enhancement. There was a positive correlation between the areas of ventricular hypertrophy and altered myocardial perfusion and these findings were more evident in the obstructive group.</p>
      <p><bold>Key Words:</bold> Myocardial perfusion; hypertrophic cardiomyopathy; comparative study; resonance imaging.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>The cardiomyopathies are diseases of unknown cause, characterized by the primary involvement of the ventricular myocardium, and, therefore, are not secondary to the pre-existing diseases of the heart or the circulation<sup>1</sup>.</p>
      <p>The hypertrophic cardiomyopathy (HCM) is characterized by the hypertrophy of the myocardium, without an apparent cause<sup>2</sup>. The disease results from genetic abnormalities established in approximately 63% of the patients<sup>3,4</sup>. The main genes related to the disease are located in chromosome 14 - the locus responsible for the heavy chain of cardiac &#946;-myosin; in chromosome 1 - o locus responsible for troponin T; and in chromosome 11, responsible for the binding of myosin to C-protein<sup>5</sup>.</p>
      <p>Usually, the disease clinically manifests in adolescence, with progressive myocardial hypertrophy during the growth spurt, but occasionally it can present in childhood or even before birth<sup>6</sup>.</p>
      <p>Patients with HCM can be classified as obstructive or non-obstructive, regarding the obstruction of the left ventricular outflow tract (LVOT). The obstruction has an important role in the prognosis and clinical evolution<sup>7</sup>, consequently being an important independent factor for the development of severe symptoms of heart failure and death<sup>2</sup>. The Doppler-echocardiographic assessment characterizes as significant the type of obstructive HCM with intraventricular gradients &gt; 30 mmHg<sup>8</sup>.</p>
      <p>Epidemiological analyses have demonstrated an estimated prevalence of the phenotypic expression of HCM in the general adult population of approximately 0.2% (1:500). It is estimated that there are 320,000 individuals with HCM in our country<sup>9</sup>. The study was carried out in a reference center in our country, which demonstrated a higher incidence of HCM in young adults, with a slight predominance of the female gender. The obstructive forms were observed in 53% of the patients<sup>9</sup>.</p>
      <p>The left ventricle (LV) hypertrophy is characteristically asymmetric, and the anterior septal wall is characteristically the one most often involved; but occasionally, the concentric form of the LV can be observed, which equally involves the septum and the free LV wall<sup>2</sup>.</p>
      <p>During a long time, the two-dimensional echocardiogram was considered the gold-standard method to evaluate the HCM<sup>10</sup>.</p>
      <p>Comparative studies between the echocardiogram and the cardiac magnetic resonance imaging (MRI) showed a higher capacity of the latter diagnostic method to study all LV segments, mainly in cases in which the disease affects other heart segments rather than the interventricular septum, as it occurs in the apical forms of hypertrophy<sup>2</sup>.</p>
      <p>The MRI allows the assessment, similarly to the echocardiogram, of the parameters of contractile ventricular function; however, it presents a higher accuracy in the calculation of volumes, mass and ejection fraction (EF), as it uses geometric models that combine the LV morphology with mathematical figures.</p>
      <p>Therefore, the MRI has become the reference technique in cases where the exact calculation of the EF is necessary<sup>10</sup>. It also allows the assessment of myocardial viability parameters and perfusion alterations<sup>11</sup>.</p>
      <p>This study aimed at evaluating the myocardial perfusion and viability in patients with HCM through the MRI technique.</p>
      <p>
        <bold>Methods</bold>
      </p>
      <p>A total of 21 patients were studied prospectively, from December 2002 to August 2005, from the Myocardiopathy Clinic Unit of Instituto do Corac&#227;o (The Heart Institute - InCor) of the School of Medicine of the University of Sao Paulo (HCFMUSP), who had a confirmed diagnosis of HCM. The diagnosis of HCM was based on the echocardiographic demonstration of LV asymmetric hypertrophy, in the absence of any heart or systemic disease that could cause it. The criterion for the diagnosis of hypertrophy was LV septal telediastolic thickness <underline>&gt;</underline> 15 mm<sup>12</sup>.</p>
      <p>The study protocol was initiated after its approval by the Ethics Committee of Hospital das Clinicas and InCor. All patients received oral and written explanations on the study proposals and objectives and all of them signed the Free and Informed Consent Form.</p>
      <p>Patients aged 18 to 60 years, with a previous diagnosis of asymmetric HCM and normal LV function, confirmed by echocardiogram, were enrolled in the study. The exclusion criteria included patients with contraindication to undergo MRI - those with hypertensive cardiomyopathy, non-sinusal rhythm, previous heart transplant, confirmed aortic stenosis, congenital heart defects, previous myocardial infarction and complex arrhythmias.</p>
      <p>The patients were divided in two groups: obstructive and non-obstructive hypertrophic cardiomyopathy. The criterion used to consider the obstruction as significant was the presence of intraventricular gradients &gt; 30 mmHg<sup>8</sup>.</p>
      <p>A venous access was obtained (Gelco 18) and connected to the pump used to administer the contrast into the antecubital vein, model Spectris MR Injector - Medrad, Pittsburgh, PA, USA. The chest was routinely prepared for the monitoring with four electrodes (Hewlett Packard MR, Massachusetts, USA) in the precordial region. The contrast used was gadopentetate dimeglumine, associated to Diethylene Triamine Penta Acetic Acid (Gd-DTPA) (Magnevist<sup>&#174;</sup> - Schering AG, Berlin, Germany). The dose used in this protocol was 0.1 mMol/kg at each phase of perfusion (stress and rest), a dose considered to be safe for patients in good clinical condition.</p>
      <p>Single Shot EPI with prospective ECG coupling was used with a repetition time of 9 ms (RT=9 ms), echo time of 4 ms (ET=4 ms), Flip angle (FA) = 40&#186;, cut thickness of 10 mm, number of excitations (NEX) of 2 to 4, field of vision (FOV) of 380 to 420 mm, and matrix of 128 x 128, interpolated to 256 lines.</p>
      <p>From the sagittal locator, the long LV axis was obtained using the echo-gradient sequence (Single Shot EPI), with prospective ECG coupling, repetition time of 9 ms (RT = 9 ms), echo time of 4 ms (ET=4 ms), Flip angle (FA) = 40&#186;, cut thickness of 10 mm, number of excitations (NEX) of 2 to 4, field of vision (FOV) of 380 to 420 mm, and matrix of 128 x 128, interpolated to 256 lines (4-chamber view) to obtain the cine MRI.</p>
      <p>From the 4-chamber view, the LV short axis planning was obtained to analyze the myocardial perfusion. The perfusion pulse sequence used was the Enhanced Fast Gradient Echo Train (EFGRET).</p>
      <p>After the acquisition of LV short axis (6 to 8 slices), the pharmacological stimulation for hyperemia was performed with dipyridamole, at a dose of 0.54 mg/kg of body weight, infused in 4 minutes. During the peak action of dipyridamole (approximately on the second minute after the end of the infusion), gadolinium was administered (Magnevist - Schering) in <italic>bolus</italic> at a dose de 0.1 mmol/kg of weight peso (0.2 ml/kg of weight).</p>
      <p>At the end of the perfusion image acquisition, aminophylin was administered at a dose of 3 mg/kg of body weight (maximum of 5 mg/kg) to antagonize the vasodilation effects of dipyridamole.</p>
      <p>The patients were considered as having returned to the initial test conditions when the heart rate (HR) returned to the levels observed at the start of the study. When the HR returned to normal, we started the acquisition at rest. In the perfusion studies during the first passage, the acquisition of the stress sequence before the rest must be carried out due to the necessity of obtaining a first passage of contrast in a muscle without contrast. We repeated the perfusion sequence with a new injection of gadolinium at a dose of 0.1 mmol/kg, (0.2 ml// kg of weight) to obtain the basal pattern of perfusion at rest.</p>
      <p>Images of the LV short axis and long axis were acquired using the sequence of Fast Card VT, coupled to ECG, FOV: 32-36, matrix: 256 x 192, thickness: 8,0 mm, Flip angle: 20, Prep Pulse (TI): variable, with a mean of 150 ms, NEX: 2, for the identification of late enhancement (LE).</p>
      <p>The images obtained were submitted to post-processing with the software Report Card 3.0, by General Electric Medical System (Milwaukee, WI, USA) to evaluate the LV segmental thickness at the short axis of the 17 segments, according to the parameters defined by the American Heart Association in 2002 (<xref ref-type="fig" rid="en_17f01-body2">Figure 1</xref>).</p>
      <p content-type="asset">
        <fig id="en_17f01-body2">
          <graphic xlink:href="1678-4170-abc-93-04-0426-00017-gf01-en.jpg"/></fig>
      </p>
      <p>To evaluate the LV mass, the epicardial and endocardial borders were traced manually, excluding the papillary muscles and trabeculations in the images of the end-diastolic phase. The LV final volume was calculated by the Simpson's method, multiplying each planimetered myocardial area by the cut thickness (10.0 mm) and adding the volumes of the sections obtained separately. The myocardial mass was calculated by multiplying the volume by the density of the myocardium (1.05/ g/ml). The calculations of ESV and EDV were carried out in a similar way, using the areas of the end-diastolic short axis and end-systolic short axis, respectively. The ejection volume was calculated by subtracting the ESV from the EDV. The global EF was calculated by dividing the contraction volume by the EDV.</p>
      <p>The myocardial images with late enhancement (LE) (white myocardium) were planimetered on the short axis after their visual identification, and the signal intensity difference &gt; 2 SD above the remaining myocardium was considered significant. These areas were measured in each one of the 17 segments, according to the segmentation used by the American Heart Association and classified regarding the distribution as diffuse or confluent.</p>
      <p>The perfusion data were analyzed through the visual identification method, associated to the signal intensity difference between the areas of normal myocardium and those with altered perfusion during the phases of stress and rest, by two experienced observers in each one of the 17 segments. The perfusion deficit areas appear black, whereas the remaining myocardium appears white with the contrast uptake. After the assessment of each observer, the data were correlated. The areas that presented LE were not considered as areas with perfusion deficit.</p>
      <p>The divergent results between the two observers were unified through a consensus.</p>
      <p>
        <bold>Statistical Analysis</bold>
      </p>
      <p>Means, standard deviations (SD), medians and minimum and maximum values were used to compare the variables and for the analysis of the continuous variables. For the categorical variables, absolute and relative frequencies were used. The pattern of LV segmental thickness was analyzed by ANOVA (analysis of variance) and by multiple comparisons using Tukey's test. The comparisons of EF, EDV and ESV were obtained through <italic>t</italic> test for independent samples. The degree of correlation between the LV thickness and LE mass was obtained by Pearson's method for each one of the segments. The perfusion assessment data at rest and at stress were presented descriptively. The level of statistical significance was set at p &lt; 0.05. The analyses were carried out using the statistical software Minitab, version 14.0.</p>
      <p>
        <bold>Results</bold>
      </p>
      <p>Of the 21 patients with HCM, 10 belonged to the non-obstructive group and 11 to the obstructive group, considering a pressure gradient at the outflow tract of 30 mmHg for the o obstructive group at the echocardiographic study. The proportion of male patients was higher in the non-obstructive group; however, it was not significant, according to Fisher's exact test (p = 0.659). There was no statistical difference regarding the mean age of the patients between the groups, according to the <italic>t</italic> test for independent samples, being 32.2 years in the non-obstructive group and 36.5 years in the obstructive group (<xref ref-type="fig" rid="c1-body2">Chart 1</xref> and <xref ref-type="fig" rid="c2-body2">2</xref>).</p>
      <fig id="c1-body2">
        <graphic xlink:href="1678-4170-abc-93-04-0426-00017-gf02-en.jpg"/></fig>
      <fig id="c2-body2">
        <graphic xlink:href="1678-4170-abc-93-04-0426-00017-gf03-en.jpg"/></fig>
      <p>The LE distribution was classified as diffuse or confluent. The diffuse type was subdivided as transseptal and right ventricular septal and the confluent type, as multifocal, sub-endocardial and of ventricular junction<sup>12</sup>. In the present study, the transseptal diffuse distribution form predominated (n = 10), followed by the confluent multifocal form (n = 6).</p>
      <p>The greatest LV thickness means were those of the basal anteroseptal, basal inferoseptal, mid-anteroseptal and mid-inferoseptal segments (2, 3, 8 and 9), and the lowest mean was the one found in the apical segment. The ANOVA test showed that there is actually a statistically significant difference among these means (p &lt; 0.001). The multiple comparisons carried out by Tukey's test confirmed the findings (<xref ref-type="fig" rid="en_17f02-body2">Figure 2</xref>).</p>
      <p content-type="asset">
        <fig id="en_17f02-body2">
          <graphic xlink:href="1678-4170-abc-93-04-0426-00017-gf04-en.jpg"/></fig>
      </p>
      <p>The mean EF in the group of patients with obstructive HCM was higher than that observed in the non-obstructive group (mean &#177;SD = 77.6&#177;7.8% in the obstructive group and 71.0&#177;12.2% in the non-obstructive group); however, there was no statistically significant difference, according to the result of the <italic>t</italic> test for independent samples (p = 0.156) (<xref ref-type="fig" rid="c3-body2">Chart 3</xref> and <xref ref-type="fig" rid="c4-body2">4</xref>).</p>
      <fig id="c3-body2">
        <graphic xlink:href="1678-4170-abc-93-04-0426-00017-gf05-en.jpg"/></fig>
      <fig id="c4-body2">
        <graphic xlink:href="1678-4170-abc-93-04-0426-00017-gf06-en.jpg"/></fig>
      <p>The ESV as well as the EDV mean was lower in the obstructive group when compared to the non-obstructive group; however, there was no statistically significant difference, according to the result of the <italic>t</italic> test for independent samples (ESV p = 0.495 and EDV p = 0.643).</p>
      <p>The correlation between the LV segmental thickness and the LE segmental mass was statistically significant in most of the assessments, that is, in the basal-anterior, anteroseptal, inferoseptal, basal-inferior, mid-anterior, mid-anteroseptal, mid-inferolateral, apical-anterior, apical-septal and apical-lateral segments (1, 2, 3, 4, 7, 8, 11, 13, 14 and 16). The correlation was positive in all these segments, that is, the greater the segmental thickness, the greater the segmental mass of the LE.</p>
      <p>The LV total mass was similar in the obstructive and non-obstructive groups, with no statistically significant difference between them (p = 0.901). The LE total mass did not present a statistically significant difference between the groups (p/ =/ 0.194), but the mean was lower in the obstructive group (19.7 g) than in the non-obstructive group (48.8 g). The linear correlation between these two parameters - LV mass and LE mass - was positive and significant, r = 0.613 (p = 0.003). Analyzing the groups separately, there was also a positive and significant correlation, with r = 0.725 (p = 0.012) for the obstructive group and r = 0.756 (p = 0.011) for the non-obstructive group.</p>
      <p>The number of segments with altered perfusion was greater in the obstructive group (63.9%) when compared to the patients in the non-obstructive group (30%). The most severely affected segments in the non-obstructive group were 3 and 4 (basal-inferoseptal and basal-inferior segments), whereas in the obstructive group, they were 2, 3 and 8 (basal anteroseptal, basal inferoseptal and mid - anteroseptal segments).</p>
      <p>Most of the patients from the assessed group did not present perfusion deficit at the rest phase, except for 1 patient from the obstructive group and 1 from the non-obstructive group. After the stress induction, 7 more patients (5 from the obstructive group and 2 from the non-obstructive group) started to present perfusion alterations in some segment. The statistical comparison by the Chi-square test showed that, during the stress perfusion, more segments were affected (p &lt; 0.001), when compared to the rest phase.</p>
      <p>There was a positive correlation between the greatest LV thickness with focal areas of perfusion deficit, being in the non-obstructive group in segments 1 (basal-anterior), 2 (basal-anteroseptal), 3 (basal inferoseptal), 7 (mid-anterior) and 8 (mid-anteroseptal); whereas in the obstructive group this correlation showed to be evident only in segments 2 (basal anteroseptal), 3 (basal inferoseptal), 14 (apical-septal) and 15 (apical-inferior). Considering the two groups together, the correlation was more evident in segments 1 (basal-anterior), 3 (basal inferoseptal), 7 (mid-anterior) and 14 (apical-septal).</p>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>The option to study the morphological and physiological aspects of the two groups of patients with HCM (obstructive and non-obstructive) by MRI was based on the premise that the differences between the interventricular gradients and between the ventricular segment thicknesses affected by hypertrophy could reveal important imaging findings, useful for the diagnostic, therapeutic and prognostic management of these patients.</p>
      <p>As expected, considering the previous selection in the present study of patients with asymmetric septal hypertrophy by the echocardiogram, the evaluation of the segmental thickness in the obstructive and non-obstructive groups showed a predominance of a greater LV thickness in segments 2 (basal-anteroseptal), 3 (basal-inferoseptal), 8 (mid-anteroseptal) and 9 (mid-inferoseptal) - (p &lt; 0.001) -, and a smaller thickness in segment 17 (apical) in the two groups. A previous study carried out an assessment of the role of MRI in determining the magnitude of LV hypertrophy in patients with HCM, comparing the MRI findings with echocardiographic data and verified that, similarly to our study, the hypertrophy predominated in the region of anterior ventricular septum in both the echocardiogram and the MRI<sup>13</sup>. Although the anterior portion of the ventricular septum is the area most commonly affected in the process of hypertrophy, the focal parietal thickening can compromise other myocardial areas, such as the posterior septum, apex, anterolateral wall, or even the posterior free wall<sup>2,14,15</sup>. Regarding the obstructive and non-obstructive groups, the overlap of the curves of the segmental ventricular thickness means showed a linear distribution that presented a similar aspect in the two groups, with slightly higher means being obtained in the obstructive group only in some segments, although without statistical significance. This information suggests that the obstruction is not a determinant factor for the increase in the myocardial thickness.</p>
      <p>There was no statistically significant difference between the EF means in the obstructive and non-obstructive groups. These data show that the obstruction at the LV outflow tract did not directly interfere with the EF, at least in our study group. It is noteworthy that, in the present study, the parameters of systolic function were evaluated at the rest phase. This is important, considering that some patients have labile obstruction, that is, absent at rest, but triggered by alterations in the pre-load, post-load and contractility.</p>
      <p>A study carried out in patients with HCM caused by the substitution of aspartic acid by asparagine (mutation Asp 175Asn) in the gene, to investigate the association between the myocardium contractile deficit and the LV hypertrophy by MRI demonstrated, similarly to the present study, that there is no difference in the EF measurement of hypertrophic patients (58%) when compared to the control group (61%); however, the authors observed that the fractional shortening values were lower in hypertrophic patients than in the controls (62%)<sup>11</sup>.</p>
      <p>In the present study, the ESV and EDV values were lower in the obstructive group when compared to the non-obstructive group, although the data were not statistically significant (ESV - p = 0.495 and EDV - p = 0.643). Literature data showed that the obstructive HCM is associated to the LV hyperdynamic contractile performance, presenting an EF level slightly above normal range, with compliance and diastolic dysfunction below the normal range, which is probably due to the several degrees of compensatory hypertrophy associated to variable phenotypic expression<sup>15</sup>.</p>
      <p>The present study showed a positive correlation between the increased ventricular segmental thickness and the presence of segmental perfusion alterations only in some segments. It is worth mentioning that it was difficult to obtain data with statistical significance, considering that the number of patients with affected segments was small in both groups.</p>
      <p>When evaluating the first-passage perfusion during the rest and stress phases in 17 patients, Sipola et al<sup>16</sup> demonstrated that the degree of perfusion deficit in patients with HCM was associated with the intensity of ventricular hypertrophy, which suggests that these defects were possibly related to these patients' phenotype. Additionally, the authors observed a negative correlation between the maximum ventricular thickness and the global and segmental reserve index of the first passage of the contrast (signal intensity <italic>vs</italic>. time curve)<sup>16</sup>. These findings suggest that the ischemia occurs more often in the hypertrophic sites and that it is a potential risk of sudden death in patients with HCM, especially the young ones. Therefore, the extension of the hypertrophy seems to be related to the increased risk of sudden death.</p>
      <p>In the present study, most patients did not present a perfusion deficit at the rest phase; however, at the stress perfusion, more segments are affected, mainly in the obstructive group.</p>
      <p>These findings have an important clinical implication, suggesting that the ischemia is a risk factor in the pathogenesis of sudden death among patients with HCM, especially the young ones. These data can also have a prognostic value, as they demonstrate that, beyond the margins of the late enhancement areas (myocardium substituted by fibrosis/collagen), there are foci of perfusion alterations (ischemic), mainly during stress.</p>
      <p>The positive correlation between the regions with greater LV segmental thickness and the LE segmental mass was verified in most of the segments evaluated in the present study. Similarly, a positive and significant correlation, r/ =/ 0.613 (p/ =/ 0.003),was demonstrated between the LV total mass and the LE total mass, also between the groups, with r/ =/ 0.725 (p = 0.012) for the obstructive group and r/ =/ 0.756 (p/ =/ 0.011) for the non-obstructive group. These findings can be related to the presence of the myocardial fascicular disarray associated to numerous tissue "grooves" and destruction of the normal circular architecture in the middle muscular layer of the hypertrophied myocardial regions<sup>17</sup>, allowing the increased deposition of contrast, associated to its slower depuration, as mentioned before. At the sites that present fibrosis and increased extracellular space, there is an increased accumulation of gadolinium-DTPA and the kinetics of its distribution is slower than in the normal myocardium. These two effects result in a delayed and persistent gadolinium concentration in areas of the heart in which the extracellular space is abnormal<sup>18,19</sup>.</p>
      <p>Moon et al<sup>20</sup> carried out a histopathological study in the heart of a 28-year-old patient with HCM that was submitted to a heart transplant and obtained images of the hypertrophic tissue through MRI. The authors found an excess of collagen interlaced with the myocardial cells that comprised up to 20% of the analyzed material. They also affirmed that there was a preferential distribution for the mesocardium, more than the endocardium or the epicardium. Also, according to this report, there was a similar distribution of the myocardial fibers that showed disarray, but this finding was independent from the presence or not of the collagen. The most relevant aspect, however, was that the areas with higher presence of LE corresponded to those in which there was a higher presence of collagen, reinforcing the hypothesis that the higher contrast intensity at the late phase, after the injection of the paramagnetic contrast medium, corresponds to the regions in which there is a higher presence of collagen<sup>20</sup>.</p>
      <p>In agreement to the present study, several authors confirmed the presence of LE in patients with HCM, demonstrating the positive correlation between the increased ventricular wall thickness and LE extension<sup>21,22</sup>.</p>
      <p>
        <bold>Conclusion</bold>
      </p>
      <p>This study demonstrated that the LE was capable of effectively evaluating the global parameters of systolic function, myocardial perfusion and viability in HCM. It was demonstrated that the ventricular segments most severely affected by hypertrophy are the septal ones and that this distribution is similar in the obstructive and non-obstructive groups, although the first group presented greater mean thickness.</p>
      <p>The regions with greater LV segmental thickness also presented greater LE segmental mass.</p>
      <p>Although there was no statistical significance, there were more segments with perfusion alterations in the group with obstructive HCM, mainly after the stress induction.</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This article is part of the thesis of doctoral submitted by Clarissa Almeida Sarmento, from Instituto do Cora&#231;&#227;o (INCOR) da Universidade de S&#227;o Paulo (USP).</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Realce tard&#237;o y perfusi&#243;n mioc&#225;rdica en cardiomiopat&#237;a hipertr&#243;fica (comparaci&#243;n entre grupos)</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>FUNDAMENTO: La resonancia magn&#233;tica es un m&#233;todo eficaz para estudio de la cardiomiopat&#237;a hipertr&#243;fica. OBJETIVO: Evaluar, por la resonancia magn&#233;tica, los par&#225;metros de funci&#243;n sist&#243;lica, perfusi&#243;n y viabilidad mioc&#225;rdica en pacientes portadores de cardiomiopat&#237;a hipertr&#243;fica, comparando los grupos con y sin obstrucci&#243;n en la v&#237;a de salida del ventr&#237;culo izquierdo. M&#201;TODO: Veinte y un pacientes con diagn&#243;stico de cardiomiopat&#237;a hipertr&#243;fica realizaron estudios de funci&#243;n, viabilidad y perfusi&#243;n mioc&#225;rdica en las fases de estr&#233;s y de reposo por la resonancia magn&#233;tica. RESULTADOS: Los segmentos ventriculares m&#225;s comprometidos por la hipertrofia fueron los de la regi&#243;n septal. El grupo obstructivo present&#243; distribuci&#243;n segmental de espesor mioc&#225;rdico semejante al no obstructivo, pero con mayores promedios que el primer grupo. El promedio de la fracci&#243;n de eyecci&#243;n de los pacientes del grupo obstructivo fue mayor que el grupo no obstructivo, mientras que los promedios de los vol&#250;menes sist&#243;lico y diast&#243;lico finales se hallaron menores en el grupo obstructivo. Hubo correlaci&#243;n positiva entre el espesor de los segmentos del ventr&#237;culo y la masa segmental del realce tard&#237;o. La inducci&#243;n de estr&#233;s determin&#243; aumento del n&#250;mero de segmentos con alteraci&#243;n de perfusi&#243;n, y esa alteraci&#243;n fue m&#225;s evidente en el grupo obstructivo. CONCLUSI&#211;N: Los segmentos ventriculares con mayor espesor son los septales. Las regiones hipertr&#243;ficas est&#225;n asociadas a la mayor extensi&#243;n de realce tard&#237;o. Hubo correlaci&#243;n positiva entre las &#225;reas de hipertrofia ventricular y perfusi&#243;n mioc&#225;rdica alterada, y estos hallazgos fueron m&#225;s evidentes en el grupo obstructivo.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Perfusi&#243;n mioc&#225;rdica</kwd>
        <kwd>cardiomiopat&#237;a hipertr&#243;fica</kwd>
        <kwd>estudio comparativo</kwd>
        <kwd>imagen de resonancia magn&#233;tica</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO ORIGINAL</bold>
      </p>
      <p>
        <fn id="top-body3">
          <label>
            <bold>Realce tard&#237;o y perfusi&#243;n mioc&#225;rdica en cardiomiopat&#237;a hipertr&#243;fica (comparaci&#243;n entre grupos</bold>
          </label>
          <p>
            <bold>Clarissa Almeida Sarmento Barbosa<sup>I</sup>; Cl&#225;udio Campi de Castro<sup>I</sup>; Luiz Francisco Rodrigues de &#193;vila<sup>I</sup>; Jos&#233; Rodrigues Parga Filho<sup>I</sup>; Domingos Mohanad Hattem<sup>II</sup>; Edmundo Arteaga Fernandez<sup>I</sup></bold>
          </p>
        </fn>
      </p>
      <p><sup>I</sup>Faculdade de Medicina da Universidade de S&#227;o Paulo (USP) - Instituto do Cora&#231;&#227;o (Incor), S&#227;o Paulo, SP</p>
      <p><sup>II</sup>Funda&#231;&#227;o Universit&#225;ria de Cardiologia do Rio Grande do Sul (FUCRS), Porto Alegre, RS - Brasil</p>
      <p>Correspond&#234;ncia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p><bold>FUNDAMENTO: </bold> La resonancia magn&#233;tica es un m&#233;todo eficaz para estudio de la cardiomiopat&#237;a hipertr&#243;fica.</p>
      <p><bold>OBJETIVO:</bold> Evaluar, por la resonancia magn&#233;tica, los par&#225;metros de funci&#243;n sist&#243;lica, perfusi&#243;n y viabilidad mioc&#225;rdica en pacientes portadores de cardiomiopat&#237;a hipertr&#243;fica, comparando los grupos con y sin obstrucci&#243;n en la v&#237;a de salida del ventr&#237;culo izquierdo.</p>
      <p><bold>M&#201;TODO: </bold> Veinte y un pacientes con diagn&#243;stico de cardiomiopat&#237;a hipertr&#243;fica realizaron estudios de funci&#243;n, viabilidad y perfusi&#243;n mioc&#225;rdica en las fases de estr&#233;s y de reposo por la resonancia magn&#233;tica.</p>
      <p><bold>RESULTADOS: </bold> Los segmentos ventriculares m&#225;s comprometidos por la hipertrofia fueron los de la regi&#243;n septal. El grupo obstructivo present&#243; distribuci&#243;n segmental de espesor mioc&#225;rdico semejante al no obstructivo, pero con mayores promedios que el primer grupo. El promedio de la fracci&#243;n de eyecci&#243;n de los pacientes del grupo obstructivo fue mayor que el grupo no obstructivo, mientras que los promedios de los vol&#250;menes sist&#243;lico y diast&#243;lico finales se hallaron menores en el grupo obstructivo. Hubo correlaci&#243;n positiva entre el espesor de los segmentos del ventr&#237;culo y la masa segmental del realce tard&#237;o. La inducci&#243;n de estr&#233;s determin&#243; aumento del n&#250;mero de segmentos con alteraci&#243;n de perfusi&#243;n, y esa alteraci&#243;n fue m&#225;s evidente en el grupo obstructivo.</p>
      <p><bold>CONCLUSI&#211;N: </bold> Los segmentos ventriculares con mayor espesor son los septales. Las regiones hipertr&#243;ficas est&#225;n asociadas a la mayor extensi&#243;n de realce tard&#237;o. Hubo correlaci&#243;n positiva entre las &#225;reas de hipertrofia ventricular y perfusi&#243;n mioc&#225;rdica alterada, y estos hallazgos fueron m&#225;s evidentes en el grupo obstructivo.</p>
      <p><bold>Palabras clave: </bold> Perfusi&#243;n mioc&#225;rdica; cardiomiopat&#237;a hipertr&#243;fica; estudio comparativo; imagen de resonancia magn&#233;tica.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>Las cardiomiopat&#237;as son enfermedades de causas desconocidas que se caracterizan por una implicaci&#243;n primaria del miocardio ventricular, sin ser, por lo tanto, secundarias a las enfermedades preexistentes del coraz&#243;n o de la circulaci&#243;n<sup>1</sup>.</p>
      <p>La cardiomiopat&#237;a hipertr&#243;fica (CMH) se caracteriza por la hipertrofia del miocardio sin causa aparente<sup>2</sup>.</p>
      <p>La enfermedad resulta de anormalidades gen&#233;ticas comprobadas en aproximadamente el 63% de los pacientes<sup>3,4</sup>. Los principales genes relacionados a la enfermedad est&#225;n ubicados en el cromosoma 14 - el <italic>locus</italic> responsable de la cadena pesada de la &#946;-miosina cardiaca; en la cromosoma 1 - el <italic>locus</italic> responsable de la troponina T; y en la cromosoma 11, responsable de la uni&#243;n de la miosina a la prote&#237;na C<sup>5</sup>.</p>
      <p>Habitualmente, la enfermedad se manifiesta cl&#237;nicamente en la adolescencia, con hipertrofia mioc&#225;rdica progresiva durante el per&#237;odo de crecimiento r&#225;pido, pero ocasionalmente puede presentarse en la infancia o hasta aun antes del nacimiento<sup>6</sup>.</p>
      <p>Los pacientes con CMH se pueden clasificar en obstructivos y no-obstructivos, en cuanto a la obstrucci&#243;n al flujo sangu&#237;neo en la v&#237;a de salida del ventr&#237;culo izquierdo (VI). La obstrucci&#243;n juega un importante rol en el pron&#243;stico y en la evoluci&#243;n cl&#237;nica<sup>7</sup>, y es, por lo tanto, un factor independiente importante en el desarrollo de s&#237;ntomas severos de insuficiencia cardiaca y de muerte<sup>2</sup>. El estudio Doppler-ecocardiogr&#225;fico caracteriza como significativo el tipo de CMH obstructiva con gradientes intraventriculares de m&#225;s que 30 mmHg<sup>8</sup>.</p>
      <p>Investigaciones epidemiol&#243;gicas evidenciaron prevalencias estimadas de la expresi&#243;n fenot&#237;pica de la CMH, en la poblaci&#243;n adulta en general, de aproximadamente 0,2% (1:500). Se presume que hay cerca de 320 mil portadores de la molestia en nuestro pa&#237;s<sup>9</sup>. Se llev&#243; a cabo un estudio en un centro de referencia de nuestro medio que demostr&#243; mayor incidencia de la CMH en adultos j&#243;venes, con discreto predominio en el sexo femenino. Las formas obstructivas se observaron en el 53% de los pacientes<sup>9</sup>.</p>
      <p>La hipertrofia del ventr&#237;culo izquierdo (VI) es caracter&#237;sticamente asim&#233;trica, con el compromiso mayor de la pared septal anterior, sin embargo se puede encontrar ocasionalmente la forma conc&#233;ntrica del VI que implica igualmente el septo y la pared libre del ventr&#237;culo<sup>2</sup>.</p>
      <p>Durante mucho tiempo, el ecocardiograma bidimensional se consider&#243; como el m&#233;todo de imagen "patr&#243;n oro" para la evaluaci&#243;n de la CMH<sup>10</sup>.</p>
      <p>Los estudios comparativos entre el ecocardiograma y la resonancia magn&#233;tica (RM) cardiaca evidenciaron una mayor capacidad de este &#250;ltimo m&#233;todo diagn&#243;stico para estudiar de forma completa todos los segmentos del VI, principalmente en los casos en que la afecci&#243;n interesa a otros segmentos del coraz&#243;n, que no el septo interventricular, como ocurre en las formas apicales de hipertrofia<sup>2</sup>.</p>
      <p>La RM permite evaluar, de forma semejante al ecocardiograma, los par&#225;metros de funci&#243;n ventricular contr&#225;ctil, sin embargo presenta mayor exactitud en el c&#225;lculo de vol&#250;menes, masa y fracci&#243;n de eyecci&#243;n (FE), ya que utiliza modelos geom&#233;tricos combinando la morfolog&#237;a del VI con figuras matem&#225;ticas. Por lo tanto, la RM se convirti&#243; en la t&#233;cnica de referencia en los casos en que el c&#225;lculo exacto de la fracci&#243;n de eyecci&#243;n es necesario<sup>10</sup>. La RM permite a&#250;n la evaluaci&#243;n de los par&#225;metros de viabilidad mioc&#225;rdica y de alteraciones perfusionales<sup>11</sup>.</p>
      <p>Este estudio tuvo como objetivo evaluar la perfusi&#243;n y la viabilidad mioc&#225;rdica en pacientes con CMH por medio del m&#233;todo de RM.</p>
      <p>
        <bold>M&#233;todos</bold>
      </p>
      <p>Se estudiaron a 21 pacientes, de forma prospectiva, durante el per&#237;odo de diciembre de 2002 a agosto de 2005, provenientes de la Unidad Cl&#237;nica de Miocardiopat&#237;as del Instituto do Cora&#231;&#227;o (InCor) de la Facultad de Medicina de la Universidad de S&#227;o Paulo (HCFMUSP), con diagn&#243;stico confirmado de CMH. El diagn&#243;stico de CMH tom&#243; como base la demostraci&#243;n ecocardiogr&#225;fica de hipertrofia asim&#233;trica del VI, en la ausencia de cualquier enfermedad cardiaca o sist&#233;mica capaz de ocasionarla. Se consider&#243; como criterio para el diagn&#243;stico de hipertrofia el grosor telediast&#243;lico del septo del VI <underline>&gt;</underline> 15 mm<sup>12</sup>.</p>
      <p>Ese protocolo de estudio se ha iniciado tras aprobaci&#243;n de la Comisi&#243;n de &#201;tica del HC y del InCor. Cada paciente recibi&#243; una explicaci&#243;n oral y otra escrita sobre las propuestas y los objetivos del trabajo y firm&#243; el Formulario de Consentimiento Informado.</p>
      <p>Se incluyeron a pacientes con edad de 18 a 60 a&#241;os, diagn&#243;stico previo de CMH asim&#233;trica y funci&#243;n de VI normal, confirmada por el ecocardiograma. Se excluyeron a los pacientes con contraindicaci&#243;n absoluta para la realizaci&#243;n de RM -aquellos con cardiomiopat&#237;a hipertensiva, ritmo no sinusal, transplante cardiaco previo, estenosis a&#243;rtica confirmada, defectos cardiacos cong&#233;nitos, infarto de miocardio previo y arritmias complejas. Se dividieron a los pacientes en dos grupos: hipertr&#243;ficos obstructivos y no obstructivos. El criterio utilizado para considerar obstrucci&#243;n significativa fue la presencia de gradientes intraventriculares de m&#225;s que 30 mmHg<sup>8</sup>.</p>
      <p>Se obtuvo v&#237;a de acceso venoso (jelco 18) conectada a la bomba inyectora para la administraci&#243;n de contraste en la vena antecubital, modelo Spectris MR Injector -Medrad, Pittsburgh, PA, USA. El t&#243;rax fue rutinariamente preparado para el monitoreo con cuatro electrodos (Hewlett Packard MR, Massachusetts, USA) en la regi&#243;n precordial.</p>
      <p>El contraste utilizado fue el gadopentetato de dimeglumina, asociado al &#225;cido dietilentriamino pentaac&#233;tico (Gd-DTPA) (Magnevist<sup>&#174;</sup> - Schering AG, Berlin, Alemania). La dosis utilizada en este protocolo fue de 0,1 mMol/kg en cada etapa de perfusi&#243;n (estr&#233;s y reposo), dosis considerada como segura en pacientes con buena condici&#243;n cl&#237;nica.</p>
      <p>Se obtuvieron secuencias localizadoras en tres planos (<italic>Single Shot</italic> EPI), con acoplamiento de ECG prospectivo con tiempo de repetici&#243;n de 9 ms (TR = 9 ms), tiempo de eco de 4 ms (TE = 4 ms), <italic>Flip angle</italic> (FA) = 40&#186;, espesor de corte de 10 mm, n&#250;mero de excitaciones (NEX) de 2 a 4, campo de visi&#243;n (FOV) de 380 a 420 mm, y matriz de 128 x 128, interpoladas para 256 l&#237;neas.</p>
      <p>Teniendo en cuenta el localizador sagital, se obtuvo el eje largo del VI con el empleo de la secuencia de gradiente eco (<italic>Single Shot</italic> EPI), con acoplamiento de ECG prospectivo con tiempo de repetici&#243;n de 9 ms (TR = 9 ms), tiempo de eco de 4 ms (TE = 4 ms), <italic>Flip angle</italic> (FA) = 40&#186;, espesor de corte de 10 mm, n&#250;mero de excitaciones (NEX) de 2 a 4, campo de visi&#243;n (FOV) de 380 a 420 mm, y matriz de 128 x 128, interpoladas para 256 l&#237;neas (corte en 4 c&#225;maras) para obtenci&#243;n de la cine RM.</p>
      <p>A partir del corte 4 c&#225;maras, se hizo la planificaci&#243;n del eje corto del VI para el an&#225;lisis de la perfusi&#243;n mioc&#225;rdica. La secuencia de pulso de perfusi&#243;n utilizada fue <italic>Enhanced Fast Gradient Echo Train</italic> (EFGRET).</p>
      <p>Tras la adquisici&#243;n en eje corto del VI (6 a 8 cortes), la estimulaci&#243;n farmacol&#243;gica para hiperemia se llev&#243; a cabo con dipiridamol en la dosis de 0,54 mg/kg del peso corporal, infundido en 4 minutos. En el pico de acci&#243;n del dipiridamol (aproximadamente en el segundo minuto tras el t&#233;rmino de la infusi&#243;n), se administr&#243; gadol&#237;nio (Magnevist - Schering) en <italic>bolus</italic> en la dosis de 0,1 mmol/kg de peso (0,2 ml/kg de peso).</p>
      <p>Al final de la adquisici&#243;n de las im&#225;genes de perfusi&#243;n, administramos aminofilina en la dosis de 3 mg/kg de peso corporal (m&#225;ximo de 5 mg/kg) para antagonizar los efectos vasodilatadores del dipiridamol. Se ten&#237;a en cuenta que el paciente hab&#237;a retornado a las condiciones iniciales del examen cuando la frecuencia cardiaca (FC) volv&#237;a a los niveles observados al principio del estudio. Cuando la FC volvi&#243; al normal, iniciamos la adquisici&#243;n en reposo. En los estudios de perfusi&#243;n de primer paso, la adquisici&#243;n de la secuencia de estr&#233;s antes del reposo se debe realizar por la necesidad de obtenerse un primer paso de contraste en un m&#250;sculo sin contraste. Repetimos la secuencia de perfusi&#243;n con la nueva inyecci&#243;n de gadolinio en la dosis de 0,1 mmol/kg, (0,2 ml/kg de peso) para la obtenci&#243;n de est&#225;ndar basal de la perfusi&#243;n reposo.</p>
      <p>Se tomaron las im&#225;genes del eje corto y eje largo del VI utilizando la secuencia Fast Card VT, acoplado al ECG, FOV: 32-36, matriz: 256 x 192, espesor: 8,0 mm, <italic>Flip angle</italic>: 20, <italic>Prep Pulse</italic> (TI): variable, con promedio de150 ms, NEX: 2, para la identificaci&#243;n del realce tard&#237;o (RT).</p>
      <p>Las im&#225;genes obtenidas fueron sometidas a postprocesamiento con el <italic>software</italic> Report Card 3.0, de propiedad comercial de la General Eletric Medical System (Milwaukee, WI, EUA) para la evaluaci&#243;n del espesor de los segmentos del VI en el eje corto de los 17 segmentos, seg&#250;n los par&#225;metros definidos por la American Heart Asociation en 2002 (<xref ref-type="fig" rid="f1-body3">Fig.1</xref><italic>).</italic></p>
      <p content-type="asset">
        <fig id="f1-body3">
          <graphic xlink:href=""/>
        </fig>
      </p>
      <p>Para la evaluaci&#243;n de la masa del VI, se delinearon los bordes epic&#225;rdicos y endoc&#225;rdicos, excluyendo los m&#250;sculos papilares y las trabeculaciones en las im&#225;genes de la fase diast&#243;lica final. El volumen final del VI se calcul&#243; por el m&#233;todo de Simpson, se multiplic&#243; cada &#225;rea mioc&#225;rdica planimetrada por el espesor de corte (10,0 mm) y se sum&#243; los vol&#250;menes de las secciones obtenidas separadamente. La masa mioc&#225;rdica se calcul&#243; multiplicando el volumen por la densidad del miocardio (1,05 g/ml). Los c&#225;lculos del VSF y del VDF se llevaron a cabo de manera similar, utilizando las &#225;reas de eje corto diast&#243;lico final y sist&#243;lico final, respectivamente. Se calcul&#243; el volumen eyectivo al sustraer el VSF del VDF. Se calcul&#243; la fracci&#243;n FE global con la divisi&#243;n del volumen contracci&#243;n por el VDF.</p>
      <p>Las im&#225;genes de miocardio con realce tard&#237;o (RT) (miocardio blanco) se planimetraron en el eje corto tras la identificaci&#243;n visual de &#233;stas, y se consider&#243; como significativa la diferencia de intensidad de se&#241;al &gt; 2 desviaciones est&#225;ndares superiores del remanente del miocardio. Se midieron estas &#225;reas en cada uno de los 17 segmentos de acuerdo con la segmentaci&#243;n utilizada por la American Heart Association y se las clasificaron en cuanto a la distribuci&#243;n en difusa y confluente.</p>
      <p>Los datos de perfusi&#243;n se evaluaron, con el m&#233;todo de identificaci&#243;n visual asociado a la diferencia de la intensidad de se&#241;al entre las &#225;reas de miocardio normal y las de perfusi&#243;n alterada en las fases de reposo y estr&#233;s, por dos observadores expertos en cada uno de los 17 segmentos. Las &#225;reas de d&#233;ficit de perfusi&#243;n se vuelven negras, mientras que el restante del miocardio sigue color blanco con la captaci&#243;n del contraste. Tras la evaluaci&#243;n de cada observador, se realiz&#243; la correlaci&#243;n de los datos. No se consideraron como &#225;reas de d&#233;ficit de perfusi&#243;n aquellos que presentaban RT. Los resultados divergentes entre los observadores se unificaron de manera consensual.</p>
      <p>
        <bold>An&#225;lisis estad&#237;stico</bold>
      </p>
      <p>Para comparaci&#243;n de las variables continuas, se utilizaron promedio, desviaci&#243;n est&#225;ndar (DE), mediana y valores m&#237;nimo y m&#225;ximo. Para las variables categ&#243;ricas, se utilizaron frecuencias absoluta y relativa. El est&#225;ndar de espesor de los segmentos del VI se analiz&#243; por las t&#233;cnicas ANOVA (an&#225;lisis de varianza) y de comparaciones m&#250;ltiples por el m&#233;todo de Tukey. Las comparaciones de la FI, VDF y VSF se tuvieron por medio de la prueba t para muestras independientes. El grado de correlaci&#243;n entre el espesor del VI y la masa del RT se obtuvo por el m&#233;todo de Pearson, para cada uno de los segmentos. Los datos de la evaluaci&#243;n de la perfusi&#243;n en reposo y en estr&#233;s se presentaron de modo descriptivo. Se consider&#243; como significancia estad&#237;stica para niveles de p &lt; 0,05. Los an&#225;lisis se efectuaron con el software estad&#237;stico Minitab, versi&#243;n 14.0.</p>
      <p>
        <bold>Resultados</bold>
      </p>
      <p>De los 21 pacientes con CMH, 10 formaron parte del grupo no obstructivo y 11 del grupo obstructivo, teniendo en cuenta el gradiente l&#237;mite en la v&#237;a de salida de 30 mmHg para el grupo obstructivo en estudio ecocardiogr&#225;fico. La proporci&#243;n de pacientes del sexo masculino fue mayor en el grupo no obstructivo, sin embargo no significante, de acuerdo con la prueba exacta de Fisher (p = 0,659). No hubo diferencia estad&#237;stica entre la edad promedio de los pacientes entre los grupos, seg&#250;n la prueba t para muestras independientes, con 32,3 a&#241;os en el grupo no obstructivo y 36,5 a&#241;os no obstructivo. (<xref ref-type="fig" rid="g1-body3">Gr&#225;ficos 1</xref> y <xref ref-type="fig" rid="g2-body3">2</xref>).</p>
      <fig id="g1-body3">
        <graphic xlink:href=""/>
      </fig>
      <fig id="g2-body3">
        <graphic xlink:href=""/>
      </fig>
      <p>La distribuci&#243;n del RT se clasific&#243; en difusa y confluente. El tipo difuso se subdividi&#243; en transeptal y septal ventricular derecho, y el confluente, en multifocal, subendoc&#225;rdico y de la uni&#243;n ventricular<sup>12</sup>. En el presente estudio, predomin&#243; la forma de distribuci&#243;n difusa transeptal (n = 10), seguida de la forma confluente multifocal (n = 6).</p>
      <p>Los mayores promedios de espesor del VI fueron los segmentos anteroseptal basal, inferoseptal basal, anteroseptal medial e inferoseptal medial (2, 3, 8 y 9), y el menor promedio encontrado del segmento apical. Por la prueba ANOVA, fue posible verificar que, de hecho, existe una diferencia estad&#237;stica significante entre estos promedios (p &lt; 0,001). Las comparaciones m&#250;ltiples realizadas por la prueba de Tukey confirmaron los hallazgos (<xref ref-type="fig" rid="f2-body3">Fig. 2</xref>).</p>
      <p content-type="asset">
        <fig id="f2-body3">
          <graphic xlink:href=""/>
        </fig>
      </p>
      <p>Lo promedio de la FE en el grupo de pacientes con CMH obstructiva fue mayor que en el grupo no obstructivo (promedio &#177; desviaci&#243;n est&#225;ndar = 77,6&#177;7,8% en el grupo obstructivo y 71,0&#177;12,2% en el grupo no obstructivo), sin embargo no hubo diferencia significativa de acuerdo con el resultado de la prueba t para muestras independientes para muestras independientes (p = 0,156) (<xref ref-type="fig" rid="g3-body3">Gr&#225;ficos 3</xref> y <xref ref-type="fig" rid="g4-body3">4</xref>).</p>
      <fig id="g3-body3">
        <graphic xlink:href=""/>
      </fig>
      <fig id="g4-body3">
        <graphic xlink:href=""/>
      </fig>
      <p>Tanto el promedio del VSF como el del VDF fueron menores en el grupo obstructivo cuando comparadas con el grupo no obstructivo, pero no hubo diferencia significativa de acuerdo con la prueba t para muestras independientes (VSF p = 0,495 y VDF p = 0,643).</p>
      <p>La correlaci&#243;n entre el espesor de los segmentos del VI y la masa segmental del RT fue estad&#237;sticamente significante en la mayor parte de las evaluaciones, es decir, en los segmentos basal-anterior, anteroseptal, &#237;nferoseptal, basal-inferior, anterior medial, anteroseptal medial, inferolateral medial, apical anterior, apical septal e apical lateral (1, 2, 3, 4, 7, 8, 11, 13, 14 y 16). En todos estos segmentos, la correlaci&#243;n fue positiva, o sea, cuanto mayor es el espesor de los segmentos, mayor es la masa segmental del RT.</p>
      <p>La masa total del VI fue semejante en los grupos obstructivo y no obstructivo, no habiendo diferencia estad&#237;stica significante entre ellos (p = 0,901). La masa total del RT tambi&#233;n no present&#243; diferencia estad&#237;stica significante entre los grupos (p = 0,194), sin embargo el promedio fue mejor en el grupo obstructivo (19,7 g) que en el grupo no obstructivo (48,8 g). La correlaci&#243;n lineal entre estos dos par&#225;metros -masa del VI y masa del RT- fue positiva y significante, r = 0,613 (p = 0,003). Analizando los grupos separadamente, tambi&#233;n hubo correlaci&#243;n positiva y significante, con r = 0,725 (p = 0,012) para el grupo obstructivo y r = 0,756 (p = 0,011) para el grupo no obstructivo.</p>
      <p>El n&#250;mero de segmentos con perfusi&#243;n alterada fue mayor en los pacientes obstructivos (63,9%) cuando comparados con los no obstructivos (30%). Los segmentos m&#225;s comprometidos en los pacientes no obstructivos fueron los 3 y 4 (inferoseptal basal y basal inferior), mientras que en el grupo obstructivo fueron los 2, 3 y 8 (anteroseptal basal, inferoseptal basal y anteroseptal promedio).</p>
      <p>La mayor parte de los pacientes del grupo evaluado no present&#243; d&#233;ficit de perfusi&#243;n en la fase de reposo, solamente un paciente del grupo obstructivo y un del no obstructivo. Tras la inducci&#243;n del estr&#233;s, y 7 pacientes m&#225;s (5 obstructivos y 2 no obstructivos) pasaron a presentar alteraci&#243;n de perfusi&#243;n en alg&#250;n segmento. La comparaci&#243;n estad&#237;stica, por la prueba de chi-cuadrado, revel&#243; todav&#237;a que, en la perfusi&#243;n de estr&#233;s, m&#225;s segmentos son comprometidos (p &lt; 0,001), cuando comparados a la de reposo.</p>
      <p>Hubo correlaci&#243;n positiva entre el mayor espesor del VI con &#225;reas focales de d&#233;ficit de perfusi&#243;n, en el grupo no obstructivo: segmentos 1 (basal-anterior), 2 (anteroseptal basal), 3 (inferoseptal basal), 7 (medio anterior) y 8 (anteroseptal medial); mientras que en el no obstructivo esta correlaci&#243;n se hall&#243; evidente solamente en los segmentos 2 (anteroseptal basal), 3 (inferoseptal basal),14 (apical septal) y 15 (apical inferior). Teniendo en cuenta los dos grupos en conjunto, la correlaci&#243;n fue m&#225;s evidente en los segmentos 1 (basal anterior), 3 (basal inferoseptal), 7 (medio anterior) y 14 (apical septal).</p>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>La opci&#243;n por estudiar los aspectos morfol&#243;gicos y fisiol&#243;gicos de los dos grupos de pacientes portadores de CMH (obstructivos y no obstructivos) por la RM se bas&#243; en la premisa de que las diferencias entre los gradientes interventriculares y entre el espesor de los segmentos ventriculares comprometidos por la hipertrofia podr&#237;an revelar importantes hallazgos de imagen, &#250;tiles para el manejo diagn&#243;stico, terap&#233;utico y pron&#243;stico de estos pacientes.</p>
      <p>Seg&#250;n lo esperado, y teniendo en cuenta la selecci&#243;n previa en el presente estudio de pacientes con hipertrofia septal asim&#233;trica mediante el ecocardiograma, la evaluaci&#243;n del espesor de los segmentos en los grupos obstructivo y no obstructivo evidenci&#243; predominio de mayor espesor del VI en los segmentos 2 (anteroseptal basal), 3 (inferoseptal basal), 8 (anteroseptal medial) y 9 (inferoseptal medial) -(p &lt; 0,001)-, y menor espesor en el segmento 17 (apical) en los dos grupos. Un estudio previo llev&#243; a cabo una evaluaci&#243;n del rol que juega la RM en la determinaci&#243;n de la magnitud de la hipertrofia del VI en pacientes con CMH, comparando los hallazgos de la RM con los datos ecocardiogr&#225;ficos, y constat&#243; de manera semejante al nuestro estudio que la hipertrofia predomin&#243; en la regi&#243;n del septo ventricular anterior tanto en el ecocardiograma como en la RM<sup>13</sup>. Pese a que la porci&#243;n anterior del septo ventricular sea el &#225;rea m&#225;s com&#250;nmente involucrada en el proceso de hipertrofia, el espesor parietal focal puede comprometer otras &#225;reas del miocardio, como septo posterior, significancia estad&#237;stica, pared anterolateral o hasta aun la pared libre posterior<sup>2,14,15</sup>. Respecto a los grupos obstructivo y no obstructivo, la sobreposici&#243;n de las curvas de los promedios de los espesores de los segmentos ventriculares revel&#243; distribuci&#243;n lineal de aspecto semejante en los dos grupos, lo que conllev&#243; la obtenci&#243;n de promedios discretamente mayores en el grupo de los pacientes obstructivos solamente en algunos segmentos, no obstante sin &#225;pice. Este dato sugiere que la obstrucci&#243;n no es el factor determinante para el aumento del espesor mioc&#225;rdico.</p>
      <p>No hubo diferencia estad&#237;stica significante entre los promedios de la FE en los grupos de hipertr&#243;ficos obstructivos y no obstructivos. Estos datos revelan que la obstrucci&#243;n en la v&#237;a de salida del VI no interfiri&#243; directamente en la FE, por lo menos en nuestro grupo en estudio. Merece la pena se&#241;alar que, en este trabajo, los par&#225;metros de funci&#243;n sist&#243;lica se evaluaron en la fase de reposo. Este dato presenta relevancia teniendo en cuenta que algunos pacientes tienen obstrucci&#243;n h&#225;bil, es decir, ausente en el reposo, pero provocada con alteraciones en la precarga, poscarga y contractilidad.</p>
      <p>Un estudio en pacientes portadores de la CMH, ocasionada por la sustituci&#243;n del &#225;cido asp&#225;rtico con asparagina (mutaci&#243;n Asp 175Asn) en el gene, para investigar la relaci&#243;n entre el d&#233;ficit contr&#225;ctil del miocardio y la hipertrof&#237;a del VI por la RM revel&#243;, de manera semejante a este estudio, que no hay diferencia en la medici&#243;n de la FE de los pacientes hipertr&#243;ficos (58%) con relaci&#243;n al grupo control (61%), pero los estudiosos observaron que los valores de acortamiento fracional fueron menores en los pacientes hipertr&#243;ficos que en los controles (62%)<sup>11</sup>.</p>
      <p>En el presente estudio, los valores de VSD y VDF fueron menores en el grupo obstructivo cuando comparados al no obstructivo, a pesar de que los datos no son estad&#237;sticamente significantes (VSF p = 0,495 y VDF p = 0,643). Datos de la literatura evidenciaron que la CMH obstructiva est&#225; asociada al desempe&#241;o contr&#225;ctil hiperdin&#225;mico del VI, presentando nivel de FE poco superior del normal, con complacencia y disfunci&#243;n diast&#243;lica con l&#237;mites inferiores al normal, lo que probablemente resulta de los diversos grados de hipertrofia compensatoria asociada a la expresi&#243;n fenot&#237;pica variable<sup>15</sup>.</p>
      <p>En el presente estudio, hubo correlaci&#243;n positiva entre el aumento del espesor del segmento ventricular con la presencia de alteraci&#243;n de perfusi&#243;n del segmento solamente en algunos segmentos. Vale notar que hubo dificultad en obtener datos con significancia estad&#237;stica, teniendo en cuenta que el n&#250;mero de pacientes con segmentos comprometidos fue peque&#241;o en los dos grupos.</p>
      <p>Evaluando la perfusi&#243;n de primera pasaje en las fases de reposo y de estr&#233;s en 17 pacientes, Sipola et al.<sup>16</sup> demostraron que el grado del d&#233;ficit de perfusi&#243;n en pacientes con CMH estaba asociado a la intensidad de la hipertrofia ventricular, lo que sugiere que dichos defectos estaban relacionados posiblemente al fenotipo de estos pacientes. Todav&#237;a en este estudio, se observ&#243; que hubo correlaci&#243;n negativa entre el espesor ventricular m&#225;ximo y el &#237;ndice de reserva global y segmental del primer paso del contraste (intensidad de se&#241;al vs. curva de tiempo)<sup>16</sup>. Estos hallazgos sugieren que la isquemia ocurre m&#225;s en los locales hipertr&#243;ficos y es un factor de riesgo potencial a la muerte s&#250;bita entre pacientes con CMH, especialmente los j&#243;venes. De este modo, la extensi&#243;n de la hipertrofia parece estar relacionada al aumento del riesgo de muerte s&#250;bita.</p>
      <p>En el presente estudio, la mayor parte de los pacientes no present&#243; d&#233;ficit de perfusi&#243;n en la fase de reposo, sin embargo, en la perfusi&#243;n de estr&#233;s, m&#225;s segmentos se comprometen, principalmente en el grupo obstructivo. Estos hallazgos tienen implicaci&#243;n cl&#237;nica importante, al sugerir que la isquemia es factor de riesgo en la patog&#233;nesis de la muerte s&#250;bita entre pacientes con CMH, especialmente los j&#243;venes. Estos datos pueden tambi&#233;n tener valor pron&#243;stico, ya que evidencian que, adem&#225;s de las m&#225;rgenes de las &#225;reas de realce tard&#237;o (miocardio sustituido por fibrosis/col&#225;geno), hay focos de alteraci&#243;n de la perfusi&#243;n (isqu&#233;mico), principalmente durante el estr&#233;s.</p>
      <p>La correlaci&#243;n positiva entre las regiones con mayor espesor de los segmentos del VI y la masa segmental del RT se verific&#243; en la mayor parte de los segmentos evaluados en el presente estudio. Se evidenci&#243;, de manera similar, la correlaci&#243;n positiva y significante, r = 0,613 (p = 0,003), entre la masa total del VI y la masa total del RT, incluso entre los grupos, con r = 0,725 (p = 0,012) para el grupo obstructivo y r = 0,756 (p = 0,011) para el grupo no obstructivo. Estos hallazgos pueden estar relacionados a la presencia de desarreglo fascicular mioc&#225;rdico asociado a numerosas "hendiduras" tisulares y destrucci&#243;n de la arquitectura circular normal en la camada muscular promedio en las regiones de miocardio hipertrofiado<sup>17</sup>, permitiendo el dep&#243;sito aumentado del contraste asociado a la depuraci&#243;n m&#225;s lenta de &#233;ste, seg&#250;n mencionado anteriormente. En los locales en los que hay fibrosis y aumento del espacio extracelular, hay mayor acumulaci&#243;n del gadolinio-DTPA, y la cin&#233;tica de distribuci&#243;n de &#233;ste es m&#225;s lenta que en el miocardio normal. Estos dos efectos resultan en una concentraci&#243;n del gadolinio retardada y persistente, en &#225;reas del coraz&#243;n en las que el espacio extracelular es anormal<sup>18,19</sup>.</p>
      <p>Moon et al.<sup>20</sup> realizaron el estudio histopatol&#243;gico en el coraz&#243;n de un paciente de 28 a&#241;os con CMH que fue sometido a transplante cardiaco con obtenci&#243;n de im&#225;genes de RM del tejido hipertr&#243;fico. Los investigadores encontraron exceso de col&#225;geno entremezclado con las c&#233;lulas mioc&#225;rdicas que compon&#237;an hasta el 20% del material examinado. Ellos tambi&#233;n afirmaron que hab&#237;a distribuci&#243;n preferencial para el mesocardio, m&#225;s que el endocardio o en el epicardio. Todav&#237;a seg&#250;n este relato, hab&#237;a distribuci&#243;n semejante de las fibras mioc&#225;rdicas que se hallaban desarregladas, pero este hallazgo era independientemente de la presencia o no del col&#225;geno. El aspecto m&#225;s relevante, adem&#225;s, es el de que las &#225;reas con mayor presencia de RT correspond&#237;an a aquellas en las que exist&#237;a mayor presencia de col&#225;geno, reforzando la hip&#243;tesis de que la mayor intensidad de contraste en la fase tard&#237;a, tras la inyecci&#243;n del medio del contraste paramagn&#233;tico, corresponde a las regiones en las que hay mayor presencia de col&#225;geno<sup>20</sup>.</p>
      <p>De igual modo que en el presente estudio, diversos autores confirmaron la presencia de RT en pacientes con CMH, evidenciando la correlaci&#243;n positiva entre aumento del espesor de la pared ventricular y extensi&#243;n del RT<sup>21,22</sup>.</p>
      <p>
        <bold>Conclusi&#243;n</bold>
      </p>
      <p>Este estudio comprob&#243; que la RM fue capaz de evaluar de modo eficaz los par&#225;metros globales de funci&#243;n sist&#243;lica, perfusi&#243;n y viabilidad mioc&#225;rdica en la CMH.</p>
      <p>Se evidenci&#243; que los segmentos ventriculares m&#225;s comprometidos por la hipertrofia son los septales y que esta distribuci&#243;n es semejante en los grupos obstructivo y no obstructivo, sin embargo con espesores promedios mayores en el primer grupo.</p>
      <p>Las regiones con mayor espesor de los segmentos del VI presentaron tambi&#233;n mayor masa segmental del RT.</p>
      <p>Pese a que no hay significancia estad&#237;stica, hubo mayor n&#250;mero de segmentos con alteraci&#243;n de perfusi&#243;n en el grupo con CMH obstructiva, principalmente tras la inducci&#243;n del estr&#233;s.</p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>El presente estudio no tuvo fuentes de financiaci&#243;n externas.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>Este art&#237;culo forma parte de tesis de Doctorado de Clarissa Almeida Sarmento por el Instituto do Cora&#231;&#227;o (INCOR) de la Universidade de S&#227;o Paulo (USP).</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
</article>
